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The Endogenous Cannabinoid System: A Budding
Source of Targets for Treating Inflammatory and
Neuropathic Pain
Giulia Donvito1, Sara R Nass2, Jenny L Wilkerson1, Zachary A Curry1, Lesley D Schurman1,
Steven G Kinsey2 and Aron H Lichtman*,1
1

Department of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University,
Richmond, VA, USA; 2Department of Psychology, West Virginia University, Morgantown, WV, USA

A great need exists for the development of new medications to treat pain resulting from various disease states and types of
injury. Given that the endogenous cannabinoid (that is, endocannabinoid) system modulates neuronal and immune cell
function, both of which play key roles in pain, therapeutics targeting this system hold promise as novel analgesics. Potential
therapeutic targets include the cannabinoid receptors, type 1 and 2, as well as biosynthetic and catabolic enzymes of the
endocannabinoids N-arachidonoylethanolamine and 2-arachidonoylglycerol. Notably, cannabinoid receptor agonists as well
as inhibitors of endocannabinoid-regulating enzymes fatty acid amide hydrolase and monoacylglycerol lipase produce reliable
antinociceptive effects, and offer opioid-sparing antinociceptive effects in myriad preclinical inflammatory and neuropathic pain
models. Emerging clinical studies show that ‘medicinal’ cannabis or cannabinoid-based medications relieve pain in human
diseases such as cancer, multiple sclerosis, and fibromyalgia. However, clinical data have yet to demonstrate the analgesic
efficacy of inhibitors of endocannabinoid-regulating enzymes. Likewise, the question of whether pharmacotherapies aimed at
the endocannabinoid system promote opioid-sparing effects in the treatment of pain reflects an important area of research.
Here we examine the preclinical and clinical evidence of various endocannabinoid system targets as potential therapeutic
strategies for inflammatory and neuropathic pain conditions.
Neuropsychopharmacology Reviews (2018) 43, 52–79; doi:10.1038/npp.2017.204; published online 8 November 2017

INTRODUCTION
Chronic pain, such as inflammatory or neuropathic pain,
represents a complicated condition that not only diminishes
quality of life but also comes at great economic cost. The
mechanisms of pathological pain are complex and characterized by both peripheral and central neuronal alterations
and neuroimmune activation, which modulates in the
initiation and maintenance of chronic pain. Glial cells,
including microglia, astrocytes, and oligodendrocytes, located within the central nervous system (CNS), as well as
Schwann cells located in the peripheral nervous system
(PNS), modulate inflammation after nerve injury (Machelska
and Celik, 2016). Following injury, neuronal inflammation
and reparatory mechanisms of neural tissues induce a state
of peripheral hyperexcitability in primary afferent nociceptors. Additionally, these peripheral nociceptors synapse with
*Correspondence: Dr AH Lichtman, Department of Pharmacology and
Toxicology, Medical College of Virginia Campus, Virginia Commonwealth
University, Richmond, VA 23298-0613, USA, Tel: +804 828 8480, Fax:
+804 828 2117, E-mail: aron.lichtman@vcuhealth.org
Received 10 April 2017; revised 24 August 2017; accepted 27 August
2017; accepted article preview online 31 August 2017
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neurons found within the dorsal horn of the spinal cord that
undergo dramatic functional alterations, due to the loss of
activity of inhibitory neurons. When this loop persists in an
enduring way, it results in a persistent pain, which is often
resistant to treatments. Indeed, the lack of efficacy of
conventional pharmacotherapies to reduce pain, and the
significant side effects associated with available medications,
creates an unmet need, which has fueled drug discovery
efforts for novel analgesics.
A large body of preclinical research demonstrates the
effectiveness of cannabinoids in rodent models of acute and
chronic inflammatory pain, as well as neuropathic pain
(Richardson, 2000). In comparison, few published studies
have examined the antinociceptive effects of cannabinoids in
nonhuman primates. In the rhesus monkey warm water tail
withdrawal paradigm, the endogenous cannabinoid arachidonoylethanolamine (anandamide; AEA), the primary active
constituent of cannabis Δ9-tetrahydrocannabinol (THC),
and the high efficacy synthetic cannabinoid receptor agonist
WIN55,212-2 produce dose-dependent antinociceptive effects (Manning et al, 2001; Vivian et al, 1998). Other studies
also demonstrate that THC and another high efficacy
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cannabinoid receptor agonist, CP55,940, evoke antinociceptive effects in rhesus monkeys (Li et al, 2008; Maguire and
France, 2014, 2016).
Several clinical studies have demonstrated the analgesic
effects of cannabinoids in human disease states, including
pain associated with diabetes, chemotherapy, multiple
sclerosis, and fibromyalgia (Lynch and Ware, 2015;
Whiting et al, 2015). However, cannabinoids lack efficacy
for acute pain (for example, dental pain, postoperative pain,
and so on (Stevens and Higgins, 2017)). The primary
psychoactive constituent of cannabis, THC (Mechoulam and
Gaoni, 1965), and certain other plant-derived or synthetic
psychoactive cannabinoids bind cannabinoid (CB1 and CB2)
receptors (Devane et al, 1988; Matsuda et al, 1990; Munro
et al, 1993). These cannabinoid receptors belong to the G
protein-coupled superfamily and are heterogeneously distributed throughout the CNS and PNS. CB1 receptors are
highly expressed on presynaptic neurons in the brain (Tsou
et al, 1998), spinal cord (Farquhar-Smith et al, 2000), and
dorsal root ganglia (Hohmann and Herkenham, 1999;
Sañudo-Peña et al, 1999). In contrast, CB2 receptors are
primarily expressed in immune cells, including myeloid,
macrophage, microglia, lymphoid, and mast cells (Piomelli,
2003). Expression of endocannabinoid receptors on various
CNS cell types is shown in Figure 1.
The most studied endogenous ligands that bind cannabinoid receptors are AEA (Devane et al, 1992) and 2arachidonoylglycerol (2-AG) (Mechoulam et al, 1995;
Sugiura et al, 1995). Although several biosynthetic pathways
have been proposed for AEA production, rate-limiting
biosynthetic enzyme(s) remain to be identified (Blankman
and Cravatt, 2013). In contrast, diacylglycerol lipase (DAGL)
α and β transform diacylglycerols into 2-AG (Bisogno et al,
2003; Gao et al, 2010; Tanimura et al, 2010). AEA and 2-AG
are rapidly hydrolyzed by fatty acid amide hydrolase (FAAH)
(Cravatt et al, 1996, 2001), and monoacylglycerol lipase
(MAGL) (Dinh et al, 2002), respectively. Besides serving as
the major catabolic enzyme of AEA, FAAH hydrolyzes other
bioactive lipids, such as N-palmitoylethanolamine (PEA)
(Fezza et al, 2008), which does not bind cannabinoid
receptors, but functions as an endogenous ligand for
peroxisome proliferator receptor-α (PPAR-α) (Lo Verme
et al, 2005). In addition to being the primary hydrolytic
enzyme for 2-AG (Dinh et al, 2002), MAGL is a rate-limiting
enzyme in the production of free arachidonic acid in brain,
liver, and lung, but not in the gastrointestinal tract or other
organs (Nomura et al, 2011). Thus, MAGL inhibitors can
produce antinociceptive and anti-inflammatory actions
through increased levels of 2-AG-stimulating cannabinoid
receptors, and decreased levels of arachidonic acid and its
pro-inflammatory metabolites. A schematic representation
of key endocannabinoid-regulating enzymes is presented in
Figure 2.
Here we review current knowledge regarding the antinociceptive effects of cannabinoids in inflammatory and
neuropathic preclinical studies of pain as well as clinical
evaluations. It is noteworthy that there is a growing interest

in potential therapeutic effects of another cannabis constituent, cannabidiol (CBD), which is included in Sativex, a
drug containing approximately equal parts of THC and CBD.
Preclinical studies testing combinations of THC and CBD, as
well as clinical studies using Sativex to demonstrate antiinflammatory (Lodzki et al, 2003; Malfait et al, 2000; Xiong
et al, 2012) and antinociceptive effects (King et al, 2017;
Langford et al, 2013; Lehmann et al, 2017; Serpell et al, 2014;
Ward et al, 2014) are reported in the literature. However, as
CBD does not bind cannabinoid receptors, this review will
not discuss this phytocannabinoid at length. In particular, we
focus on the well-established antinociceptive effects of
cannabimimetic agents in carrageenan- and lipopolysacharide (LPS)-induced acute inflammatory pain models, as well
as in longer-term inflammatory pain models (for example,
complete Freund’s adjuvant-induced chronic inflammation
and collagen-induced arthritis). We also discuss neuropathic
pain associated with nerve injury, diabetes, chemotherapeutic agents, and migraine. Table 1 provides an overview of a
selected range of rodent assays to assess nociceptive behavior
in preclinical inflammatory and neuropathic pain models.
Furthermore, we cover the opioid-sparing effects of cannabinoids in terms of cannabinoid effectiveness in reducing
opioid doses, thereby reducing side effects of each drug
without reducing overall antinociceptive efficacy. Finally,
assorted clinical trials testing cannabis in neuropathic pain
patients are discussed.

ACUTE AND CHRONIC INFLAMMATORY
PAIN
Anti-Inflammatory Effects: In Vitro Assays
Pharmacological agents acting on various components of the
endocannabinoid system exert anti-inflammatory effects,
primarily through suppression of cytokine production,
inhibition of cell proliferation, and induction of cell apoptosis (Nagarkatti et al, 2009). The inflammatory response to
insult must be tightly regulated in order to minimize damage
to healthy tissues. Thus, in addition to proinflammatory
cytokines, activated immune cells produce and release antiinflammatory mediators, including interleukin-10 (IL-10),
which are regulated by the endocannabinoid system (Klein,
2005). Endocannabinoids mediate inflammation by regulating cytokines at different steps throughout the inflammatory
response (Cabral and Griffin-Thomas, 2009). For example,
THC and AEA suppress proinflammatory cytokines and
enhance anti-inflammatory cytokines in both innate and
adaptive immune responses (Cabral and Griffin-Thomas,
2009). AEA inhibits microglial nitric oxide (NO) synthesis
through the mitogen-activated protein kinase pathway
(Eljaschewitsch et al, 2006) and inhibits tumor necrosis
factor α (TNF-α) activation of the transcription nuclear
factor kappa B (Sancho et al, 2003). However, cannabinoids
may also increase production of proinflammatory cytokines,
depending on the model, dose, and drug probe (Klein, 2005).
For example, in vitro studies THC inhibits proinflammatory
...................................................................................................................................................
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Figure 1. Endocannabinoid system localization by CNS cell type. Drugs acting upon cannabinoid receptors and the endocannabinoid-regulating
enzymes are determined not only by drug class, efficacy, affinity, and potency, but also by cellular compartmentalization of the drug target. 2-AG, 2arachidonyl glycerol; ABHD6, α/β-hydrolase domain-6; ABHD12, α/β-hydrolase domain-12; AEA, anandamide; CB1, cannabinoid receptor 1; CB2,
cannabinoid receptor 2; DAGL-α, diacylglycerol lipase-α; DAGL-β, diacylglycerol lipase-β; FABP, fatty acid binding protein; FAAH, fatty acid amide
hydrolase; MAGL, monoacylglycerol lipase; NAPE, N-arachidonoyl phosphatidylethanolamine; PPAR-α, peroxisome proliferator-activated receptor alpha;
TRPV1, transient receptor potential cation channel subfamily V member 1. Question marks refer to conflicting evidence to support the targets cellular
localization.
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Figure 2. Enzymatic regulation of endocannabinoids and primary targets. Endogenous cannabinoids are enzymatically regulated, produced, and
released on demand. Anandamide and 2-AG bind and activate CB1 and CB2 receptors. Anandamide also binds and activates transient receptor potential
cation channel subfamily V member 1 (TRPV1). Diacylglycerol lipase (DAGL) alpha and beta synthesize 2-arachidonoylglycerol. N-acyl
phosphatidylethanolamine-selective phospholipase D (NAPE-PLD*) is one of several enzymes proposed to synthesize anandamide. Monoacylglycerol
lipase (MAGL), alpha/beta-hydrolase domain containing (ABHD) 6 and 12 hydrolyze 2-AG to create arachidonic acid. Several enzymes, including
cyclooxygenase (COX) 1 and 2 and lipoxygenases (LOXs) convert arachidonic acid into bioactive lipids. COX2 also converts anandamide to prostaglandinethanolamides, and 2-AG to prostaglandin glycerol esters. Thick blue or red lines with arrows represent major degradative pathways for 2-AG and
anandamide, respectively. Dashed lines with arrows represent other degradative pathways. Reverse arrows (Y) represent activation of receptor targets of
each endocannabinoid.

cytokine synthesis at nanomolar concentrations, but stimulates proinflammatory cytokine synthesis at micromolar
concentrations, indicating a biphasic effect (Berdyshev et al,
1997).
Macrophages are the main producers of proinflammatory
cytokines, especially during the early stages of the innate

immune response. THC and AEA attenuate LPS-stimulated
IL-6, and NO release from macrophages in vitro (Chang
et al, 2001). Similarly, during the adaptive immune response,
T cells produce cytokines. The endocannabinoid system also
modulates inflammation by shifting the balance of CD4+
‘Helper’ T cells through suppression of Th1 proinflammatory
...................................................................................................................................................
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TABLE 1 Assays to Evaluate Nociceptive Behavior in Rodents
Test

Stimulus

Description

Ref

Tail flick

Thermal, heat

The measured parameter is the latency, in seconds, for tail flick reflex following tail
exposure to a heat stimulus.

D’Amour and Smith, 1941

Hot plate

Thermal, heat

The measured parameter is usually the latency for paw licking or the first observed
response (ie, jump) when the animal is placed on a hot surface (52 or 55 °C).

O’Callaghan and
Holtzman, 1975

Acetone test

Thermal, cold

The measured parameter is usually the number or frequency of brisk foot
withdrawal after applying a drop of acetone to a hind paw.

Choi et al, 1994

Von-Frey test

Mechanical

The measured parameter is usually the withdrawal threshold (g) after the randomly
application of a series of calibrated monofilaments on the hind paws for 3 s.

Murphy et al, 1999

Randal-Selitto

Mechanical

The measured parameter is usually the withdrawal threshold (g) or vocalization
when the hind paw is placed between a fixed element, such as a surface or a blunt
point, and a mobile blunt point exerting a controlled pressure.

Randall and Selitto, 1957

Conditioned place preference (CPP)
Conditioned place avoidance (CPA)

Motivational

During a preconditioning phase, subjects are placed in a box consisting of a neutral
middle chamber and two chambers on either side (visually, texturally, and olfactory
different). Drug conditioning trials are run with the drug given in one of the two
chambers, which provides the opportunity for the development of an association.
During testing, amount of time spent in the drug-paired chamber indicates a
preference. The measured parameter is the place preference score (PPS).

Roux et al, 2003

Intracranial self-administration (ICSS)

Motivational

Under pain condition, animals are provided with intravenous catheters and allowed
to perform an operant response such as the depression of a lever to self-administer
a drug. This technique has been used extensively to evaluate a drug’s propensity for
abuse.

Carlezon and Chartoff,
2007

Nesting test

Pain-depressed
behavior

The measured parameter is usually the number of area cleared in the animal cage
wherein 6 nestlet pieces are placed in a period of 100 s. The nesting procedure is
an evaluation of pain-related depressed behavior.

Negus et al, 2015

activity and promotion of Th2 anti-inflammatory activity
(Yuan et al, 2002). THC decreases Legionella pneumophilainduced production of the proinflammatory cytokines,
gamma interferon (IFN-γ) and IL-12, typically released from
the Th1 cells, and increase production of the anti-inflammatory cytokine IL-4, released by Th2 cells in mouse
splenocytes. Selective antagonists of both the CB2 receptor,
SR144528, and CB1 receptor, rimonabant, reverses the
suppression of IFN-γ and IL-12, indicating that these
receptors play necessary roles in the modulation of proinflammatory cytokines (Klein et al, 1985). These results
suggest that endogenous cannabinoids inhibit the production
of proinflammatory cytokines and increase the production of
anti-inflammatory cytokines throughout the inflammatory
response.
The endocannabinoid system also modulates the inflammatory response through the suppression of immune cell
activation, proliferation and migration, and the activation of
immune cell apoptosis. Administration of the cannabinoid
receptor agonist, CP55,940 decreased the migration of rat
macrophages through a CB1 and CB2 receptor mechanism in
both in vivo and in vitro models (Sacerdote et al, 2000).
Furthermore, THC indirectly inhibits the activation of T
helper cells by suppressing antigen presentation in macrophages (McCoy et al, 1995).
Cannabinoids also inhibit the cell-specific proliferation of
B and T cells (Cabral and Griffin-Thomas, 2009; Klein
and Cabral, 2006). For example, THC inhibited the
proliferation of human T cells stimulated with antigenprimed dendritic cells (Yuan et al, 2002). Similarly, THC
inhibits the proliferation of mouse splenic T cells stimulated
...................................................................................................................................................
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by concanavalin A, and B cells stimulated by LPS (Klein et al,
1985). In addition to inhibiting cell proliferation, THC
induces apoptosis of mouse macrophages, T cells, and
B cells in primary splenic and thymic cultures (McKallip
et al, 2002).
Cannabinoids elicit analgesic and immunomodulatory
effects in arthritis and other inflammatory diseases.
Fibroblast-like synoviocytes (FLS) reside in synovial tissue.
FLSs from patients affected by rheumatoid arthritis and
osteoarthritis express the CB1 and CB2 receptors (Richardson
et al, 2008). Both receptors are expressed on chondrocytes
and within the joint cartilage and subchondral bone of
patients with osteoarthritis (Dunn et al, 2014, 2016). Within
rheumatoid arthritis synovial tissue, CB2 receptors are
expressed on macrophages, CD4+ T cells, CD8+ T cells,
and B cells (Fukuda et al, 2014). Interestingly, AEA and 2AG are present in the synovial fluid of patients affected by
both rheumatoid arthritis and osteoarthritis, but not in
healthy controls, suggesting an upregulation in response to
inflammation and cartilage degradation (Richardson et al,
2008). The presence of cannabinoid receptors in arthritic
joints suggests that the endocannabinoid system plays a
compensatory role in this disease. However, the lack of
highly selective CB2 receptor antibodies limits interpretation
of some studies. Thus, the use of stringent negative controls
is crucial for the correct detection and quantification of
protein targets (Marchalant et al, 2014).
In arthritic synovial tissue, FLSs release matrix metalloproteinases that degrade the cartilage extracellular matrix
and pro-inflammatory cytokines (Karouzakis et al, 2006).
The release of matrix metalloproteinases and cytokines are
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attenuated by cannabinoids in vitro (Lowin et al, 2015,
2016; Selvi et al, 2008). In FLSs derived from patients
with rheumatoid arthritis and osteoarthritis, synthetic
cannabinoid receptor agonists (CP55,940, WIN55,212, or
Ajulemic acid) or AEA (Lowin et al, 2015) attenuate TNF-α
stimulated production of the proinflammatory cytokines
IL-6 and IL-8, and matrix degrading enzymes matrix
metalloproteinases-1, -3, and -9 (Johnson et al, 2007;
Lowin et al, 2015, 2016; Selvi et al, 2008). The selective
CB2 receptor agonists HU-308 and JWH133 also reduce IL-6,
IL-8, and matrix metalloproteinases-3 from TNFα or IL-1β
stimulated rheumatoid arthritis and osteoarthritis FLS
(Fukuda et al, 2014; Gui et al, 2014). AEA's attenuation of
IL-6 and IL-8 is blocked by the TRPA1 antagonist A967079,
but not by CB1 or CB2 receptor antagonists (Lowin et al,
2015), indicating that cannabinoids modulate inflammation
through multiple pathways.
In rheumatoid arthritis FLSs stimulated by TNFα, AEA
attenuates the phosphorylation of p38 and ERK1/2, but not
cJUN, indicating a decrease in mitogen-activated protein
kinase activation (Lowin et al, 2015). The selective CB2
receptor agonist HU-308 also inhibited IL-1β stimulated
phosphorylation of ERK 1/2 and p38 mitogen-activated
protein kinase in FLS from rheumatoid arthritis patients
(Gui et al, 2014). These studies suggest that cannabinoids
may reduce arthritic inflammation and cartilage degradation
by the release of proinflammatory cytokines and matrixdegrading enzymes from FLSs in the synovium through the
modulation of ERK1/2 and p38 mitogen-activated protein
kinase activity.
Cannabinoids may also reduce cartilage degradation in
arthritis through the regulation of chondrocytes. In bovine
nasal cartilage stimulated by IL-1β, the cannabinoid receptor
agonists WIN-55,212-2 and HU-210 prevented the breakdown of proteoglycan and collagen (Mbvundula et al, 2006).
WIN-55,212-2 also inhibits the production of PGE2, expression of iNOS, and the activation of nuclear factor kappa B in
bovine chondrocytes (Mbvundula et al, 2006). Furthermore,
incubation of WIN-55,212-2 alone or in combination with
IL-1β decreases the expression of matrix-degrading enzyme
matrix metalloproteinases-3 and -13, and matrix metalloproteinases tissue inhibitor of metalloproteinase-1 and -2 in
osteoarthritis chondrocytes (Dunn et al, 2014). WIN-55,2122 also attenuates the production of the matrix-degrading
enzyme disintegrin and metalloprotease with thrombospondin motifs-4 from osteoarthritis chondrocytes either unstimulated or stimulated with IL-1β (Kong et al, 2016). The
attenuation of the metalloprotease with thrombospondin
motifs-4 production is reversed by the selective CB2 receptor
antagonist, JTE907, but not the selective CB1 receptor
antagonist, MJ15 indicating that CB2 plays a necessary role
in this effect. Taken together, these studies indicate that
cannabinoids may reduce cartilage degradation by attenuating the release of matrix-degrading enzymes (that is, matrix
metalloproteinases and metalloprotease with thrombospondin motifs) from chondrocytes.

Anti-Inflammatory Effects: In Vivo Assays
Acute pain models. Cannabinoids have anti-inflammatory
properties and also elicit antinociceptive effects by inhibiting
neuronal transmission in pain pathways. Cannabinoidinduced antinociception is reported in a variety of preclinical
inflammatory pain models (Table 2; also see a review by
Guindon and Hohmann, 2009), including intraplantar
injection (that is, into the ventral footpad) of the seaweed
extract carrageenan, and the Gram-negative bacterial-derived
endotoxin lipopolysaccharide (LPS). These non-self inflammogens elicit an innate immune response that results in
acute antinociception and localized edema in the affected
paw. Several assays are available to test antinociceptive
behavior in the animal models of inflammatory pain
(Table 1). For example, the synthetic cannabinoid agonist
HU-210 restores the carrageenan-induced reduction in
weight bearing in rats (Clayton et al, 2002; Elmes et al,
2005; Sofia et al, 1973). Similarly, intraplantar injection of
high-dose (that is, 25 μg) LPS induces acute, localized pain
and inflammation that is attenuated by synthetic cannabinoid agonists WIN55,212-2 and CP55,940 (Kinsey et al,
2011a; Naidu et al, 2010). These inflammatory pain assays,
along with others, have been used to investigate the acute
antinociceptive effects of cannabinoid receptor agonists, CB1
receptor-positive allosteric modulators (PAMs), inhibitors of
endocannabinoid-regulating enzymes, and inhibitors of
endocannabinoid transport.
CB2 receptor-selective agonists represent a promising
strategy to bypass the undesirable cognitive and behavioral
side effects of mixed CB1/CB2 receptor agonists. The selective
CB2 receptor agonists GW405833 and JWH133 attenuate
edema and restore weight bearing in rat paws injected with
carrageenan (Clayton et al, 2002; Elmes et al, 2005). The CB2
receptor agonist O-3223 attenuates hyperalgesia and edema
induced by intraplantar injection of LPS, and was reversed by
the CB2 receptor antagonist, SR144528, but not by rimonabant (Kinsey et al, 2011a).
CB1 receptor PAMs represent another approach to block
inflammatory pain without cannabimimetic side effects. For
example, the CB1 positive allosteric modulator ZCZ011
increases binding of orthosteric CB1 receptor agonists
(Ignatowska-Jankowska et al, 2015b). When administered
alone, ZCZ011 attenuates carrageenan-induced mechanical
allodynia, but does not elicit anti-edematous effects,
mediated by CB2 receptors. The observations that ZCZ011
does not elicit psychomimetic effects in tetrad assay or
substitute for cannabinoids in the drug discrimination
paradigm, suggesting that this compound has a reduced side
effect profile compared with orthosteric CB1 receptor
agonists (Ignatowska-Jankowska et al, 2015b).
Inhibiting endocannabinoid catabolic enzymes represents
a distinct approach from direct-acting cannabinoid receptor
agonists. In general, inhibition of FAAH or MAGL
attenuates acute inflammatory pain with reduced cannabimimetic side effects compared with direct-acting CB1
receptor agonists. For example, pharmacological inhibition
...................................................................................................................................................
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Pain model

Type

Treatment

Route Species Mechanical

Thermal Weight
bearing

Mechanism of
action

Edema

Edema
receptor

Citation

Carrageenan

Agonist

THC

p.o.

Rat

N/A

N/A

N/A

N/A

Decrease N/A

Sofia et al, 1973

HU210

i.p.

Rat

N/A

N/A

yes

CB1

Decrease CB1 & CB2

Clayton et al, 2002; Elmes et al, 2005

Phytocannabinoid

THCV

i.p.

Mouse

N/A

Plantar

N/A

Non-CB

Decrease CB2

Bolognini et al, 2010

CB1 agonist

ACEA

i.pl.

Rat

von Frey

Plantar

N/A

CB1

N/A

N/A

Gutierrez et al, 2007

N/A

Ignatowska-Jankowska et al, 2015c

ZCZ011

i.p.

Mouse

von Frey

N/A

N/A

CB1

No Δ

CB2 agonist

GW405833

i.p.

Rat

N/A

N/A

yes

CB2

Decrease CB2

Clayton et al, 2002

JWH133

i.p.

Rat

N/A

N/A

yes

CB2

Decrease CB2

Elmes et al, 2005

AM1241

i.p.

Rat

N/A

Plantar

N/A

CB2

No Δ

N/A

Bingham et al, 2007; Nackley et al,
2003; Quartilho et al, 2003

AM1241

i.pl.

Rat

von Frey

Plantar

N/A

CB2

N/A

N/A

Quartilho et al, 2003 (plantar only);
Gutierrez et al, 2007; Nackley et al,
2003 (von Frey and plantar)

CB2 inverse agonist

JTE-907

Mouse

N/A

N/A

N/A

N/A

Decrease N/A

Iwamura et al, 2001

CB2 agonist + CB1 agonist

AM1241 + ACEA

i.pl.

Rat

N/A

Plantar

N/A

N/A

Decrease CB2

Gutierrez et al, 2007

FAAH inhibition

FAAH KO

N/A

Mouse

N/A

Plantar

N/A

CB2

Decrease CB2

Lichtman et al, 2004; Wise et al, 2008

URB597

i.p.

Mouse

N/A

No

N/A

N/A

Decrease CB2

Holt et al, 2005 (edema only); Costa
et al, 2010

URB597

i.pl.

Rat

N/A

N/A

yes

PPAR-α

No Δ

URB937

i.p.

Mouse

von Frey &
pressure

Plantar

N/A

CB1

Decrease CB1 & CB2

JNJ-1661010
MAGL inhibition

FABP

N/A

N/A

Jhaveri et al, 2008
Clapper et al, 2010

Rat

N/A

Plantar

N/A

N/A

N/A

PF-3845

i.p.

Mouse

von Frey

N/A

N/A

N/A

Decrease N/A

Ghosh et al, 2013

URB602

i.p.

Mouse

N/A

Plantar

N/A

CB2

Decrease CB2

Comelli et al, 2007

JZL184

i.p.

Mouse

von Frey

N/A

N/A

CB1 & CB2

Decrease CB2

Ghosh et al, 2013

KML129

i.p.

Mouse

von Frey

N/A

N/A

CB1 & CB2

Decrease CB2

Ignatowska-Jankowska et al, 2014

SBFI26

i.p.

Mouse

N/A

Plantar

N/A

N/A

Decrease N/A

Kaczocha et al, 2014

Karbarz et al, 2009

SBFI50

i.p.

Mouse

N/A

Plantar

N/A

N/A

Decrease N/A

Kaczocha et al, 2014

FABP5/7 KO

N/A

Mouse

N/A

Plantar

N/A

PPAR-α & TRPV1

Decrease N/A

Kaczocha et al, 2015

FAAH inhibition + NSAID URB937 + Indomethacin

p.o.

Mouse

Pressure

Plantar

N/A

N/A

Decrease N/A

Sasso et al, 2012

PF-3845 + Diclofenac

i.p.

Mouse

von Frey

N/A

N/A

CB1 & CB2

N/A

Grim et al, 2014

PF-3845 + JZL184

i.p.

Mouse

von Frey

N/A

N/A

CB1 & CB2

Decrease CB2

SA-57

i.p.

Mouse

von Frey

N/A

N/A

CB1 & CB2

Decrease CB2

Wilkerson et al, 2017

FAAH inhibition + TRPV1
antagonism

AA-5-HT

i.p.

Mouse

Randall-Stiletto

Plantar

N/A

CB1 & TRPV1

Decrease TRPV1

Costa et al, 2010

FAAH inhibition + TRPV1
antagonism

AA-5-HT

i.pl.

Mouse

no

No

N/A

N/A

N/A

N/A

Costa et al, 2010

FAAH & sHE inhibition

URB937 + TPPU

p.o.

Mouse

pressure

Plantar

N/A

N/A

Decrease N/A

Sasso et al, 2015

WIN55212-2

i.p.

Mouse

N/A

HP

N/A

N/A

Decrease N/A

Naidu et al, 2010

FAAH & MAGL inhibition

CB2 agonist

Ghosh et al, 2015

CP55,940

i.p.

Mouse

N/A

HP

N/A

CB1 & CB2

Decrease CB2

Kinsey et al, 2011a

O-3223

i.p.

Mouse

N/A

HP

N/A

CB2

Decrease CB2

Kinsey et al, 2011a

REVIEW

LPS (high dose) Agonist

N/A
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TABLE 2 Antinociceptive Effects of Cannabinoids in Pre-Clinical Models of Acute Inflammatory Pain
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Booker et al, 2012
N/A

Abbreviations: HP, hot plate; i.p., intraperitoneal; i.pl., intraplantar; N/A, not assessed; non-CB, not blocked by CB1 or CB2 receptors; p.o., given via gavage.

N/A
N/A
N/A
N/A
von Frey
Mouse
i.p.
THC
Agonist

Wilkerson et al, 2016a

Wilkerson et al, 2016a
N/A

N/A
N/A

N/A
N/A

N/A
N/A

N/A
N/A

N/A
von Frey

von Frey
Mouse

Mouse
i.pl.

i.p.

KT-109

KT-195
ABHD6 inhibition

Wilkerson et al, 2016a

Wilkerson et al, 2016a
N/A

N/A
N/A

N/A
N/A

Non-CB
N/A

N/A
N/A

N/A
von Frey

von Frey
Mouse

Mouse

N/A

i.p.
KT-109

i.pl.

DAGL-β KO
DAGL-β inhibition

Booker et al, 2012

Booker et al, 2012
N/A
N/A
N/A
N/A
N/A
von Frey

Booker et al, 2012

PF-3845

Mouse

N/A
N/A
CB1 & CB2
N/A
N/A
von Frey
i.p.
PF-3845

Mouse

Booker et al, 2012
N/A

N/A
N/A

N/A
N/A

N/A
N/A

N/A
N/A

N/A
von Frey

von Frey

i.p.
OL-135

Mouse

i.p.
URB597

Mouse

Naidu et al, 2010

Booker et al, 2012
N/A

N/A

Decrease CB2
CB1

CB1 & CB2
N/A
N/A

HP
N/A

von Frey
Mouse

Mouse
i.p.

N/A

URB597

FAAH KO
LPS (low dose) FAAH inhibition

N/A

Naidu et al, 2010
Decrease CB2
CB1
N/A
HP
N/A
Mouse
N/A
FAAH KO
LPS (high dose) FAAH inhibition

Type
Pain model

Table 2 (Continued )

Treatment

Route Species Mechanical

Thermal Weight
bearing

Mechanism of
action

Edema

Edema
receptor

Citation
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or genetic deletion of FAAH attenuates carrageenan-induced
inflammation as well as mechanical allodynia and thermal
hyperalgesia (increased sensitivity to a noxious heat
stimuli) (Ghosh et al, 2013; Karbarz et al, 2009; Lichtman
et al, 2004). FAAH inhibitors also attenuate carrageenaninduced edema, an effect that is mediated through the CB2
receptor (Holt et al, 2005; Lichtman et al, 2004). The FAAH
inhibitor URB597, or genetic deletion of FAAH, also
attenuates LPS-induced hyperalgesia and edema (Naidu
et al, 2010). The anti-hyperalgesic effect of FAAH inhibition
in the LPS model was reversed by CB1 receptor antagonism,
whereas the anti-edematous effect was reversed by CB2
antagonism (Naidu et al, 2010). Similarly, the peripherally
restricted FAAH inhibitor URB937 attenuates carrageenaninduced allodynia and hyperalgesia through a CB1
mechanism of action. However, unlike brain-permeating
FAAH inhibitors, the anti-edematous effects of URB937
are mediated by both CB1 and CB2 receptors (Clapper et al,
2010).
Similarly, inhibition of MAGL, the primary catabolic
enzyme of 2-AG (Blankman et al, 2007), attenuates
carrageenan-induced, acute paw edema and inflammatory
pain (Comelli et al, 2007; Ghosh et al, 2013; IgnatowskaJankowska et al, 2014). The selective MAGL inhibitors
JZL184 and KML129 attenuate carrageenan-induced mechanical allodynia through CB1 and CB2 receptor-dependent
mechanisms, but only CB2 receptors mediate the antiedematous effects of these inhibitors (Ghosh et al, 2013;
Ignatowska-Jankowska et al, 2014). Combining a high dose
of the FAAH inhibitor, PF-3845 with a low dose of the
MAGL inhibitor, JZL184, attenuates carrageenan induced
mechanical allodynia and paw edema in mice to a greater
degree than either drug alone (Ghosh et al, 2015). Similarly,
the dual FAAH/MAGL inhibitor SA-57 attenuates
allodynia and edema induced by intraplantar carrageenan
(Wilkerson et al, 2017). The anti-allodynic effects of
combined FAAH/MAGL inhibition are reversed by either
CB1 or CB2 receptor antagonists, whereas only a CB2
receptor antagonist reverses the anti-edematous effects of
dual FAAH/MAGL inhibition.
FAAH inhibition has also been combined with other, noncannabinoid analgesics to attenuate edema and pain in the
carrageenan model. For example, AA-5-HT, a dual FAAH
inhibitor/transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist, attenuates thermal
and mechanical hyperalgesia, as well as edema produced by
an intraplantar injection of carrageenan (Costa et al, 2010).
Epoxidized fatty acids exert anti-inflammatory and antinociceptive effects, and are metabolized by the enzyme
soluble epoxide hydrolase. Combined administration of the
peripherally-restricted FAAH inhibitor, URB937, and the
epoxide hydrolase inhibitor, TPPU, attenuates carrageenaninduced mechanical and thermal hyperalgesia, as well as,
paw edema, in a synergistic manner (Sasso et al, 2015).
Similarly, dual administration of URB937 and the nonsteroidal anti-inflammatory drug (NSAID) indomethacin synergistically attenuates hyperalgesia, allodynia, and edema
...................................................................................................................................................
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induced by intraplantar carrageenan injection (Sasso et al,
2012). Mechanical allodynia induced by carrageenan injection is also reduced by coadministration of the FAAH
inhibitor PF-3845 and the NSAID diclofenac (Grim et al,
2014). The anti-allodynic effect is blocked by SR144528 or
rimonabant, indicating that both cannabinoid receptors
mediate this antinociceptive effect (Grim et al, 2014).
Fatty acid-binding proteins (FABPs) are proposed to
transport endocannabinoids intracellularly, from the cell
membrane to the endoplasmic reticulum for hydrolysis
(Kaczocha et al, 2009). The FABP inhibitors SBFI26 and
SBFI50 attenuate carrageenan-induced acute paw edema and
thermal hyperalgesia (Kaczocha et al, 2014). Similarly,
genetic deletion of FABP5 and FABP7 reduces thermal
hyperalgesia and edema induced by carrageenan injection
(Kaczocha et al, 2015). PPAR-α and TRPV1 receptors
mediate the anti-hyperalgesic phenotypes of FABP5 (− / − )
mice and FABP7 ( − / − ) mice. These data suggest that
preventing endocannabinoid degradation through inhibition
of either their catabolic enzymes or FABPs attenuates acute
inflammatory pain.
Localized administration of low dose (ie, 2.5 μg) LPS evokes
tactile allodynia that is attenuated by FAAH inhibition
without inducing paw edema (Booker et al, 2012). Genetic
deletion of FAAH also reduces mechanical allodynia induced
by low-dose LPS, but this anti-allodynia is absent in mice
expressing FAAH only in nervous tissue (Booker et al, 2012)
and is mediated by both CB1 and CB2 receptors. Intraplantar
administration of PF-3845 also attenuates LPS-induced
allodynia (Booker et al, 2012). However, inhibition of
ABHD6, an enzyme that plays a minor role in 2-AG
degradation (Blankman et al, 2007), does not affect LPSinduced allodynia (Wilkerson et al, 2016a).
Blockade of the 2-AG biosynthetic enzyme DAGL-β also
produces antinociception in the LPS model of inflammatory
pain. Systemic or localized administration of the DAGL-β
inhibitor KT-109 reversed mechanical allodynia induced by
intraplantar injection of low-dose LPS (Wilkerson et al,
2016a). Moreover, DAGL-β ( − / − ) mice displayed an
antinociceptive phenotype in this model. The antinociceptive
effects following pharmacological inhibition or genetic
deletion of DAGL-β are possibly the result of reduced
production of proinflammatory metabolites of arachidonic
acid in macrophages. Specifically, DAGL-β is highly
expressed in macrophages, and its blockade leads to reduced
levels of 2-AG, arachidonic acid, and a variety of proinflammatory arachidonic acid metabolites and proinflammatory cytokines in these cells (Hsu et al, 2012). Importantly,
DAGL-β inhibition also blocks the LPS-induced production
of proinflammatory mediators (Hsu et al, 2012). Thus,
increasing 2-AG levels via MAGL inhibition reduces LPSinduced nociception through a cannabinoid receptor mechanism of action, while decreasing 2-AG levels in peripheral
tissue (possibly in macrophages) by inhibiting DAGL-β
reduces LPS-induced nociception by dampening the innate
immune response.

Chronic pain models. Unlike carrageenan or LPS that
only induce inflammatory pain for a period of hours to a
few days, other inflammatory pain models elicit nociceptive
behavior that may persist for weeks. Several wellcharacterized long-term inflammatory pain models include
the complete Freund’s adjuvant (CFA) model, which induces
nociception and paw swelling, osteroarthritis, produced by
intra-articular injection of monosodium iodoacetate (MIA),
and the collagen-induced arthritis (CIA) model, a wellcharacterized mouse model of inflammatory arthritis. These
models of chronic inflammatory pain lead to a variety of
changes in the endocannabinoid system. Moreover, a wide
range of cannabimimetic agents produce antinociception in
CFA and CIA inflammatory pain models (Table 3), as well as
osteroarthritis models (Table 4).
CFA administration into a ventral footpad leads to
upregulation of CB2 receptors, but not CB2 receptor mRNA
in dorsal root ganglia or ipsilateral paw tissue of rats,
suggesting that these receptors play an integral role in the
endocannabinoid modulation of chronic inflammatory pain
(Hsieh et al, 2011). Acute administration of CB2 receptor
agonists reduces CFA-induced mechanical and thermal
hyperalgesia (Hsieh et al, 2011; Valenzano et al, 2005; Yao
et al, 2008, 2009). Furthermore, intraplantar administration
of the CB2 receptor agonist JWH015 reduces allodynia and
hyperalgesia induced by CFA injection (Negrete et al, 2011).
Unexpectedly, the antinociceptive effects of this drug are
mediated by CB2 receptors and μ opioid receptors (MORs).
The observation that CFA leads to increased expression of
these receptors in the paw and dorsal root ganglia may
account for the recruitment of MORs (Negrete et al, 2011).
Systemic or intrathecal administration of NMP-181, which
acts as a CB2 receptor agonist and T-type channel inhibitor,
also attenuates CFA-induced mechanical hyperalgesia
(Gadotti et al, 2013). In another study, the CB2 receptor
agonist GW405833 was reported to produce antinoiceptive
effects through CB1 receptor mechanism of action, while CB2
receptors were dispensible (Li et al, 2017). Selective CB2
receptor agonists often possess low CB1 receptor affinity, and
when administered in vivo may activate both receptors,
particularly when administered at high doses. Thus, studies
employing CB2 receptor-selective agonists need to apply
caution by testing whether CB1 receptors contribute to any
observed effects.
Although CFA leads to an upregulation of CB2 receptors,
CB1 receptor stimulation also attenuates chronic inflammatory pain. Localized administration of the CB1 receptor
agonist ACPA attenuates CFA-induced mechanical hyperalgesia (Auh et al, 2016). Combination of ACPA and the
MOR agonist DAMGO reduces CFA-induced hyperalgesia.
However, isobolographic analyses revealed that the interaction is infra-additive, indicating that the combination is less
effective than either drug by itself (Auh et al, 2016).
In agreement with studies employing acute inflammatory
pain models, inhibition of endocannabinoid catabolic
enzymes also reduces chronic inflammatory pain. For
example, FAAH inhibition attenuates mechanically-induced
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TABLE 3 Antinociceptive Effects of Cannabinoids in Pre-Clinical Models of Chronic Inflammatory Pain
Pain
model

Type

Treatment

Route

Species

Mechanical

Thermal

Pain
receptor

Inflammation Mechanism of
action

Joint
damage

Joint
receptor

References

CIA

CBD derivatives

CBD

i.p. & p.o.

Mouse

N/A

N/A

N/A

Decrease

N/A

Decrease

N/A

Malfait et al, 2000

HU320

i.p.

Mouse

N/A

N/A

N/A

Decrease

N/A

Decrease

N/A

Sumariwalla et al, 2004

HU-444

i.p. & p.o.

Mouse

N/A

N/A

N/A

Decrease

N/A

Decrease

N/A

Haj et al, 2015

JWH133

i.p.

Mouse

N/A

N/A

N/A

Decrease

N/A

Decrease

N/A

Fukuda et al, 2014

HU-308

i.p.

Mouse

N/A

N/A

N/A

Decrease

N/A

Decrease

N/A

Gui et al, 2015

FAAH KO

N/A

Mouse

N/A

HP & Tail
immersion

N/A

Decrease

CB2

Decrease

CB2

Kinsey et al, 2011b

URB597

i.p.

Mouse

N/A

HP & Tail
immersion

CB1

Decrease

N/A

Decrease

N/A

Kinsey et al, 2011b

CB2 agonist
FAAH inhibition

AIA

CFA

Agonist

Agonist

JNJ1661010

i.p.

Mouse

N/A

N/A

N/A

Decrease

N/A

N/A

N/A

Lowin et al, 2015

THC

i.p. & p.o.
(swelling)

Rat

Pressure

N/A

CB1, CB2, &
opioid

Decrease

N/A

N/A

N/A

Sofia et al, 1973 (swelling);
Cox et al, 2007; Cox and
Welch, 2004; Smith et al,
1998

Ajulemic acid

p.o.

Rat

N/A

N/A

N/A

Decrease

N/A

Decrease

N/A

Zurier et al, 1998

AEA

i.p.

Rat

Pressure

N/A

Non-CB1

N/A

N/A

N/A

N/A

Smith et al, 1998

WIN55212-2

s.c.

Mouse

von Frey

Plantar

CB1 & CB2

N/A

N/A

N/A

N/A

Anderson et al, 2014

HU-210

i.p.

Rat

von Frey

Plantar

N/A

N/A

N/A

N/A

N/A

Jayamanne et al, 2006

i.pl.

Rat

Randall-Selitto

N/A

N/A

N/A

N/A

N/A

N/A

Auh et al, 2016

A-796260

i.p.

Rat

N/A

Plantar

CB2

N/A

N/A

N/A

N/A

Yao et al, 2008

GW405833

i.p.

Mouse & Rat von Frey (M) &
pressure (R)

N/A

CB2

N/A

CB1

N/A

N/A

Li et al, 2017; Valenzano
et al, 2005; Whiteside et al,
2005

A-836339

i.p.

Rat

N/A

Plantar

CB2

N/A

N/A

N/A

N/A

Hsieh et al, 2011

JWH015

i.pl.

Mouse

von Frey

Plantar

CB2 & MOR

N/A

N/A

N/A

N/A

Negrete et al, 2011

AM1241

i.p.

Rat

N/A

Plantar

N/A

N/A

N/A

N/A

N/A

Hsieh et al, 2011

URB597

i.p.

Rat

von Frey

Plantar

CB1 & CB2

N/A

N/A

N/A

N/A

Jayamanne et al, 2006

PF-3845

p.o.

Rat

von Frey

N/A

CB1 & CB2

N/A

N/A

N/A

N/A

Ahn et al, 2009

PF-04457845

p.o.

Rat

von Frey

N/A

CB1 & CB2

N/A

N/A

N/A

N/A

Ahn et al, 2011

URB-937

p.o.

Mouse

Pressure

Plantar

N/A

N/A

N/A

N/A

N/A

Sasso et al, 2012

Multiple targets

AM404

s.c.

Rat

Randall-Selitto

Plantar

CB1

N/A

N/A

N/A

N/A

La Rana et al, 2008

CB1 + MOR
agonist

ACPA +
DAMGO

i.pl.

Rat

Randall-Selitto;
attenuate by
antagonistic

N/A

N/A

N/A

N/A

N/A

N/A

Auh et al, 2016

CB2 agonist +
T-type channel
inhibition

NMP-181

i.p. & i.t.

Mouse

DPA

N/A

N/A

N/A

N/A

N/A

N/A

Gadotti et al, 2013

CB2 agonist +
T-type channel
inhibition

NMP-181

i.p. & i.t.

Mouse

DPA

N/A

N/A

N/A

N/A

N/A

N/A

Gadotti et al, 2013

FAAH & MAGL
inhibition

JZL195

s.c.

Mouse

von Frey

Plantar

CB1 & CB2

N/A

N/A

N/A

N/A

Anderson et al, 2014

FAAH inhibition

Endocannabinoids and pain
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ACPA

Abbreviations: AAIA, adjuvant-induced arthritis; HP, hot plate; i.p., intraperitoneal; i.pl., intraplantar; i.t., intrathecal; p.o., given via gavage; MOR, μ-opioid receptor; N/A, not assessed; s.c., subcutaneous.
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Abbreviations: xP, overexpression; i.p., intraperitoneal; s.c., subcutaneous; p.o., via gavage; no Δ, no change; N/A, not assessed.

Sophocleous et al, 2015

Sophocleous et al, 2015
Increase
N/A
N/A
N/A
N/A
N/A
Mouse
N/A
CB2 KO
CB2 antagonist
Spontaneous age related
osteroarthritis

Sophocleous et al, 2015
Decrease

Increase
N/A

N/A
N/A

N/A
N/A

N/A
N/A

N/A
N/A

N/A
Mouse

Mouse
N/A

N/A
HU-308

CB2 KO

CB2 agonist

CB2 antagonist

DMM

Malek et al, 2016

Burston et al, 2016

N/A

No Δ
N/A

N/A
N/A
N/A

CB2
Yes
CB1 & CB2

CB1 & TRPV1

von Frey

PAM
Rat

Rat
i.p.

i.p.

MJN110

OMDM-198
FAAH inhibition + TRPV1
antagonism

p.o.

MAGL inhibition

Malek et al, 2016

Ahn et al, 2011
N/A
N/A
N/A
N/A
N/A
Randall-Selitto

Schuelert et al, 2011

PF-04457845

Rat

N/A
N/A
N/A
N/A
N/A
PAM
i.p.
URB597

Rat

La Porta et al, 2013

N/A
N/A
CB1
Yes
N/A
N/A
s.c.
URB597
FAAH inhibition

Rat

La Porta et al, 2013

No Δ
N/A
N/A
N/A
CB1 KO
CB1 antagonist

N/A

Mouse

von Frey; no Δ

N/A

La Porta et al, 2013

no Δ
N/A
CB2 xP
CB2 over expression

N/A

Mouse

von Frey

N/A

N/A

N/A

Burston et al, 2013

No Δ
N/A
N/A
N/A
N/A
von Frey; augmented
Mouse
N/A
CB2 KO
CB2 antagonist

Yao et al, 2008
N/A

N/A
N/A

Yes
N/A

N/A
Yes

N/A
N/A

N/A
von Frey

N/A

s.c.
JWH133

Rat

i.p.
A-796260
CB2 agonist
MIA

Rat

Mechanical
Species
Route
Treatment
Type
Pain model

TABLE 4 Antinociceptive Effects of Cannabinoids in Preclinical Models of Osteoarthritis

Mechanism of action

Weight bearing

WB receptor

Grip force

Joint damage

References
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pain in the CFA model of inflammatory pain (Ahn et al,
2009, 2011; Jayamanne et al, 2006; Sasso et al, 2012). These
anti-allodynic effects are mediated by both the CB1 and CB2
receptors. The dual FAAH-MAGL inhibitor JZL195 reduces
mechanical allodynia and thermal hyperalgesia induced by
CFA injection (Anderson et al, 2014). The CB1 receptor
antagonist AM251 fully reverses these antinociceptive effects,
while the CB2 receptor antagonist AM630 partially reverses
these effects (Anderson et al, 2014).
Administration of CBD, or its synthetic analogs, attenuates
clinical signs of arthritis and joint damage, while having an
immunosuppressant effect in CIA (Haj et al, 2015; Malfait
et al, 2000; Sumariwalla et al, 2004). The selective CB2 receptor
agonists JWH133 and HU-308 attenuated paw swelling,
cartilage degradation, and bone erosion in mice subjected to
CIA (Fukuda et al, 2014; Gui et al, 2015). The antiinflammatory and analgesic effects of FAAH inhibition have
also been investigated in the CIA model. Wild-type mice
treated with URB597 or FAAH ( − / − ) mice subjected to CIA
show reduced thermal hyperalgesia in the hot plate and tail
immersion tests. Furthermore, chronic FAAH inhibition
reduces CIA-induced paw swelling (Kinsey et al, 2011b;
Lowin et al, 2015) and joint destruction (Kinsey et al, 2011b).
Osteoarthritis is a highly prevalent type of arthritis
characterized by synovitis, and degeneration of both articular
cartilage and subchondral bone in the joints of the hands,
knees, hips, and spine (Goldring and Goldring, 2007). MIA
induces chondrocyte death, cartilage degradation, and
chronic nociception (Burston et al, 2013). This nociception
and joint damage occur ipsilateral, but not contralateral, to
the injection site. Administration of MIA into the knee joint
leads to upregulation of CB2 and CB1 receptor mRNA in the
ipsilateral spinal cord of rats, suggesting that these receptors
undergo compensatory changes in this osteoarthritis model,
and may represent potential targets for novel osteoarthritis
treatments (Burston et al, 2013; Malek et al, 2015).
After MIA administration, CB2 ( − / − ) mice show
augmented mechanical allodynia compared with wild-type
littermates (La Porta et al, 2013). Interestingly, CB2 ( − / − )
mice also display allodynia in the contralateral paw after
MIA. This bilateral augmented allodynic response has also
been reported to occur in CB2 ( − / − ) mice subjected to
sciatic nerve injury, indicating the mirrored response is not
MIA model specific (Racz et al, 2008). By comparison, CB1
( − / − ) mice do not differ in allodynic response on the
ipsilateral or contralateral paw after MIA, supporting the role
of CB2 in the development of allodynia in osteoarthritis (La
Porta et al, 2013).
Mice overexpressing the CB2 receptor (CB2 xP) display an
attenuated MIA-induced mechanical allodynic phenotype
(La Porta et al, 2013). Furthermore, the CB2 receptor agonist
JWH133 attenuates MIA-induced allodynia and restores
weight bearing on the arthritic joint (Burston et al, 2013).
Intrathecal injection of JWH133 also attenuates the firing of
wide dynamic range neurons after MIA injection, indicating
CB2 receptor activation in the spinal cord may attenuate
MIA-induced allodynia (Burston et al, 2013).
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Osteoarthritis can also be modeled in mice by destabilization of the medial meniscus by surgically sectioning a ligament in the joint. The CB2 receptor agonist HU308 reduced
joint damage in the DMM osteoarthritis model, whereas
CB2 ( − / − ) mice developed more joint damage than wildtype mice (Sophocleous et al, 2015). By contrast, CB2 ( − / − )
mice, CB2 xP mice, and CB1 ( − / − ) mice subjected to MIAinduced arthritis do no differ from wild-type mice in the
amount of joint damage (La Porta et al, 2013). These
conflicting results may be attributed to variations in the
progression of joint destruction in the different models.
Inhibition of the major endocannabinoid catabolic
enzymes also attenuates pain in a rodent model of osteoarthritis. The FAAH inhibitor URB597 reduces MIA-induced
mechanical hyperalgesia and restores weight bearing on the
arthritic limb (Malek et al, 2015; Schuelert et al, 2011).
OMDM-198, a combined FAAH inhibitor-TRPV1 antagonist, attenuates mechanical hyperalgesia elicited by MIA
injection (Malek et al, 2015). Furthermore, MIA administration leads to upregulation of FAAH and TRPV1 mRNA in
the ipsilateral spinal cord (Malek et al, 2015). The MAGL
inhibitor MJN110 also attenuates mechanical allodynia and
restores MIA limb weight bearing. The anti-allodynic effects
of MJN110 were mediated by a CB2 receptor mechanism of
action, while CB1 receptors did not play a necessary role in
this effect. However, weight bearing was only partially
blocked by the CB2 receptor antagonist, SR144528, but fully
blocked by rimonabant, indicating a difference in receptor
mechanism (Burston et al, 2016).
Two noteworthy caveats to preclinical inflammatory pain
models are that anti-inflammatory treatments, including
manipulation of the endocannabinoid system, are often as
follows: (1) administered prior to the induction of inflammation and thus block development of inflammation; and
(2) administered repeatedly for a few days (ie, subchronically). In addition, acute manipulation of the endocannabinoid system typically reduces pain measures via CB1
receptor. These experimental limitations must be considered
when translating results from preclinical research to the
clinic.

NEUROPATHIC PAIN
Neuropathic pain is a severe chronic, debilitating condition
associated with nerve injury (for example, structural,
nutritional, toxic, infectious, or autoimmune damage) that
also develops following lesions to the CNS or PNS insult.
Neuropathic pain often manifests as a spontaneous burning,
tingling, or shooting sensation, which can be amplified by
noxious (pressure, heat, and cold), and otherwise innocuous
(touch and warm or cool temperatures) mechanical and
thermal stimuli (Jensen and Finnerup, 2014). Neuropathic
pain pathophysiology is complex and includes functional
alterations of the CNS and PNS (Cohen and Mao, 2014)
in addition to neuro-immune interactions (Austin and
Moalem-Taylor, 2010).

The dorsal horn of the spinal cord receives noxious
sensory information from primary afferent Aδ fibers (ie,
medium diameter myelinated afferents that transmit acute,
localized sharp pain sensation) and C fibers (that is, small
diameter unmyelinated afferents that convey poorly localized
delayed pain sensation) (Braz et al, 2014). The largestdiameter, myelinated primary afferent Aβ fibers transmit
innocuous mechanical stimuli (for example, light touch) and
have their terminals in the deeper lamina of the dorsal horn
and mainly target excitatory and inhibitory interneurons. On
the other hand, the superficial lamina of the dorsal horn is
abundant with terminals from C and Aδ fibers that activate
projection neurons and excitatory interneurons. Under
normal conditions, Aβ fibers do not activate nociceptive
projection neurons and do not transmit pain because of
strong suppression of signaling by inhibitory interneurons.
However, under pathological conditions (that is, peripheral
inflammation, or peripheral nerve injury; PNI), neuropathic
pain may develop. Nerve injury induces hyperexcitability,
thereby causing functional alterations in the neuronal network such as loss of function of inhibitory neurons in the
dorsal horn, and results in neuropathic pain (Prescott et al,
2014; Todd, 2010). Additionally, glial cells (innate immune
cells of the CNS), which include microglia and astrocytes,
contribute to neuropathic pain by altering inflammation and
glutamate signaling (Scholz and Woolf, 2007).
Despite recent progress, current mechanistic understanding of pain hypersensitivity caused by nerve damage remains
limited. Traditional pain medications generally lack efficacy
to treat neuropathic pain (Guirguis-Blake and Kelly, 2007),
so a great need exists for the development of new efficacious
analgesics. Also, laboratory animal models that accurately
mimic key aspects of the pain reported clinically are needed
to test candidate therapies. Assessing neuropathic pain
behavior in rodents is crucial to validate pain models and
new analgesics. Although a wide variety of laboratory animal
models of nociception (see Table 1) have been applied to
experimental neuropathic and inflammatory pain procedures, these assays generally have limited ability to reflect
fully the complexity of clinical symptoms and comorbidities.
Nevertheless, pain assessments in these models provide
valuable tools for the mechanistic understanding of neuropathic pain syndromes and remain a key step in the
discovery process for new pain medications.
Laboratory animal models have been used a variety of
preclinical studies investigating cannabinoids in neuropathic
pain models. The results of these studies highlight potentially
important roles of the endocannabinoid system in the
pathophysiology of neuropathic pain, and potential therapeutic targets to treat these conditions (Figures 1 and 2).
Using complementary genetic and pharmacological
approaches, distinct components of the endocannabinoid
system (ie, receptors and endocannabinoid-regulating enzymes) have emerged as promising targets to treat neuropathic pain (Table 5; for additional information, Guindon
and Hohmann, 2009; Rahn and Hohmann, 2009). Whether
the CB1 receptor plays a tonic role in nociception remains to
...................................................................................................................................................
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Anti-allodynic/Anti-hyperalgesic
Stimulus Modality
Target

Drug

Thermal/Heat Cold

Receptor Involvement
(Yes/No)

Species

Mechanical

CB1

CB2

Reference(s)

CP55,940

Mouse, rat

+

WIN

Rat

+

+

Y/N

Y/N

Sain et al, 2009; Scott et al, 2004

Y

N

AM1241

Mouse

+

+

Bridges et al, 2001; LaBuda and Little, 2005; Leichsenring et al, 2009; Yu et al, 2010

N

Y

Beltramo et al, 2006; Hsieh et al, 2011; Ibrahim et al, 2003

GW405833

Rat

+

Leichsenring et al, 2009

URB597

Rat

+

de Novellis et al, 2011

Spinal nerve ligation
CB1 & CB2
CB2
FAAH

+

CB1 & CB2

AEA

Mouse, rat

+

CP55,940

Rat

+

HU-210

Rat

+

WIN

Mouse, rat

+

CB2

GW405833

Mouse, rat

+

JWH133

Mouse

+

FAAH

URB597

Mouse, rat

+

PPARα

PEA

Rat

+

+

Y

N

Desroches et al, 2014b; Helyes et al, 2003
Fox et al, 2001

+

+

+

Y

Y

Fox et al, 2001; Jayamanne et al, 2006; Mitchell et al, 2005; Vuong et al, 2008

Y/N

Y/N

Desroches et al, 2014b; Fox et al, 2001; Guindon et al, 2007; Gunduz et al, 2011;
Lever et al, 2007

Y

N

Li et al, 2017; Valenzano et al, 2005; Whiteside et al, 2005

Y

Klauke et al, 2014; Yamamoto et al, 2008

Y

N

Desroches et al, 2008, 2014b

Y

Helyes et al, 2003

Y

N

Kinsey et al, 2011a; De Vry et al, 2004

Y/N

Adamson Barnes et al, 2016; Brownjohn and Ashton, 2012; Costa et al, 2004;
Hama and Urban, 2004; Herzberg et al, 1997; Kazantzis et al, 2016; Lim et al, 2003;
Linsell et al, 2015; Liu and Walker, 2006; Pascual et al, 2005; La Rana et al, 2008

Endocannabinoids and pain
G Donvito et al

Partial sciatic nerve ligation (pSNL)

.....................................................................................................................................................................

64

...................................................................................................................................................

Neuropsychopharmacology REVIEWS

TABLE 5 Antinociceptive Effects of Cannabinoids in Preclinical Models of Neuropathic Pain

Chronic constriction injury (CCI)
CB1 & CB2

CB2

FAAH

Rat

+

+

Mouse, rat

+

+

+

Y

WIN

Mouse, rat

+

+

+

Y

THC

Mouse, rat

+

+

+

Y

AM1241

Rat

+

Starowicz et al, 2012

Kinsey et al, 2013; Mao et al, 2000; De Vry et al, 2004; Xie et al, 2016
Wilkerson et al, 2012b

AM1710

Rat

+

Wilkerson et al, 2012a

GW405833

Rat

+

Brownjohn and Ashton, 2012; Hu et al, 2009

JWH-015

Mouse

+

PF-3845

Mouse, rat

+

URB597

Mouse, rat

+

+

+

URB937

Mouse

+

+

JZL184

Mouse, rat

+

+

MJN110

Mouse

+

+

Y

Hervera et al, 2010

+

+
Y

Y

Ghosh et al, 2015; Grim et al, 2014; Kinsey et al, 2010; Malek et al, 2016; Schlosburg
et al, 2010

+

Y/N

Y/N

Adamson Barnes et al, 2016; Caprioli et al, 2012; Kinsey et al, 2009; Russo et al,
2007; Starowicz et al, 2012, 2013; Toniolo et al, 2014

Y

N

Clapper et al, 2010; Sasso et al, 2012

+

Y

Y/N

Adamson Barnes et al, 2016; Crowe et al, 2015; Ghosh et al, 2015; IgnatowskaJankowska et al, 2015a; Kinsey et al, 2009, 2010, 2013; Schlosburg et al, 2010;
Toniolo et al, 2014

Y

Y/N

Ignatowska-Jankowska et al, 2015a; Wilkerson et al, 2016b

REVIEW

MAGL

AEA
CP55,940

REVIEW

Table 5 (Continued )
Anti-allodynic/Anti-hyperalgesic
Stimulus Modality
Thermal/Heat Cold

Receptor Involvement
(Yes/No)

Target

Drug

Species

Mechanical

CB1

Dual FAAH
& MAGL

JZL195

Mouse

+

SA-57

Mouse

+

+

Wilkerson et al, 2017

DAGLβ

KT-109

Mouse

+

+

Wilkerson et al, 2016a

PPARα

PEA

Mouse

+

+

CB2

+

Reference(s)
Adamson Barnes et al, 2016

Y

N

Y

N

Di Cesare Mannelli et al, 2013; Costa et al, 2008

Cisplatin-induced peripheral neuropathy
CB1 & CB2

CB2
FAAH
MAGL

AEA

Mouse

+

THC

Mouse

+

Khasabova et al, 2012
Harris et al, 2016

WIN

Rat

+

AM1710

Rat

+

Y

Y/N

N

Y

JWH133

Rat

+

Deng et al, 2012

Y

Vera et al, 2013

URB597

Mouse, rat

+

+

URB937

Rat

+

+

Y

Y/N

Guindon et al, 2013; Khasabova et al, 2012

Y

Y

Guindon et al, 2013

JZL184

Mouse, rat

+

+

Y

Y/N

Guindon et al, 2013; Khasabova et al, 2014

CP55,940

Mouse

+

WIN

Rat

+

+

Y

Y

Deng et al, 2015a

THC

Mouse

+

AM1241

Rat

+

AM1710

Mouse, rat

+

+

Vera et al, 2013

Paclitaxel-induced peripheral neuropathy

AM1714

Rat

+

DAGLβ

KT-109

Mouse

+

PPARα

PEA

Mouse

+

Y

Pascual et al, 2005

+
+
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CB2

+

Deng et al, 2015b
N

Y

Rahn et al, 2008

N

Y

Deng et al, 2012, 2015b

N

Y

Rahn et al, 2008
Wilkerson et al, 2016a

N

N

Donvito et al, 2016

Vincristine-induced peripheral neuropathy
CB1 & CB2

WIN

Rat

+

Y

Y

Rahn et al, 2007

CB2

AM1241

Rat

+

N

Y

Rahn et al, 2007

Y/N

Y

Diabetic (streptozotocin-induced) peripheral neuropathy
CB1 and CB2 THC

Mouse, rat

WIN

Mouse, rat

+

+

CB2

AM1241

Rat

+

JWH-015

Mouse

+

+

FAAH

URB597

Rat

+

+

Williams et al, 2008

+

Bujalska, 2008; Doğrul et al, 2004; Ikeda et al, 2013; Jahanabadi et al, 2016;
Mohammadi-Farani et al, 2010; Ulugol et al, 2004; Vera et al, 2012; Vincenzi et al,
2013
Bujalska-Zadrożny et al, 2015; Bujalska, 2008

+

Y

Castany et al, 2016
Hasanein et al, 2009
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Positive analgesic results for mechanical, thermal, and cold stimuli are denoted with a ‘+’. In general, the mechanical stimuli refer to von Frey filament, pressure (Randal Stiletto) or similar testing. Thermal stimuli generally
included focused beams of light, hotplate plantar withdrawal or tail flick, depending on the type of neuropathy. Cold stimuli referred to positive results using plantar acetone, cold plate or similar testing. Cannabinoid (CB1 or
CB2) receptors involvement includes results from mice lacking the gene of interest or experiments using pharmacologic antagonists. Full or partial blockade of analgesic effects is denoted with a ‘Y’ (yes). Negative results are
reported with an ‘N’ (no). Conflicting results between experiments are denoted ‘Y/N’ (yes/no). See listed references for more details. Anandamide; AEA. Delta-9-tetrahydrocannabinol; THC. Palmitoylethanolamide; PEA.
WIN55,212.; WIN.

Rat
URB937

+

+

Mouse

Mouse

PF-3845

URB597

FAAH

Nitroglycerin-induced migraine and hyperalgesia

+
Mouse
PEA
PPARα

+
Rat

Rat
MJN110
MAGL

URB937

+

+

Greco et al, 2015

(Nozaki et al, 2015)

Nozaki et al, 2015

Y

Y

(Donvito et al, 2015)
Y
Y

Sasso et al, 2015

Niphakis et al, 2013

CB2
CB1
Thermal/Heat Cold
Mechanical
Species
Drug
Target

Table 5 (Continued )

Anti-allodynic/Anti-hyperalgesic
Stimulus Modality

Receptor Involvement
(Yes/No)

Reference(s)
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be established. However, it is noteworthy that CB1 ( − / − )
mice do not display apparent altered nociception
(Nadal et al, 2013), but rather a pain-induced increase in
time spent in the dark area of the light/dark test, and
decreased time and travel distance in the open area
of the zero-maze apparatus. Additionally, CB1 ( − / − ) mice
show a reduction in sucrose preference and home cage
activity (Rácz et al, 2015). Strikingly, selective CB1 receptor
deletion in peripheral nociceptors leads to enhanced pain
behavior as well as diminished antinociceptive effects of
cannabinoid receptor agonists, suggesting an important role
of peripheral CB1 receptors in neuropathic pain (Agarwal
et al, 2007).
CB2 receptor deletion also leads to varying effects on
neuropathic pain. CB2 ( − / − ) mice show exacerbated pain
behavior, while CB2 overexpression in the CNS attenuates
neuropathic pain (Racz et al, 2008). However, other studies
using knockout mice or selective inhibitors of CB1 or CB2
receptors show no alterations of nociceptive behavior in
neuropathic pain models (Kinsey et al, 2009, 2010) though
ceiling effects and other methodological differences between
studies may have precluded the detection of enhanced
nociceptive behavior. CB1 and CB2 receptor agonists produce
antinociceptive effects in laboratory animal models of
neuropathic pain (Nadal et al, 2013). On the other hand,
the development and expression of neuropathic pain were
not modified in FAAH or MAGL ( − / − ) mice (Nadal et al,
2013; Schlosburg et al, 2010).
This section describes the commonly used models of
neuropathic pain: chronic constriction injury (CCI) of the
sciatic nerve, streptozotocin (STZ)-induced diabetic neuropathy, chemotherapy-induced neuropathy, and migraine
headache. Additionally, we discuss studies reporting the
antinociceptive effects of various pharmacological manipulations of the endocannabinoid system in these models.

Nerve Injury Models
In rodents, one of the most common experimental
approaches for inducing peripheral neuropathy is traumatic
nerve injury (full or partial) via ligation, transection, or
compression of the sciatic nerve (Bennett and Xie, 1988;
Seltzer et al, 1990; Wall et al, 1979) or its distal branches (Lee
et al, 2000). The partial sciatic nerve ligation model was
established by Seltzer, in which approximately half of the rat
sciatic nerve is ligated, generally in the proximal region of the
thigh, leading to the development of mechanical allodynia
and thermal hyperalgesia (Seltzer et al, 1990).
Another well-characterized model is chronic constriction
injury (CCI), which inflicts reproducible nerve injury
without complete denervation (Bennett and Xie, 1988).
Originally developed in rats, one or more sutures are loosely
tied around the common sciatic nerve at intervals of 1–
2 mm. Rats subjected to CCI show behavioral signs
interpreted as spontaneous pain, including moderate autotomy, guarding, licking and, limping of ipsilateral hind paw in
addition to avoidance of placing weight on the injured side.
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Within 2 days following surgery, rats show evidence of
mechanical allodynia, thermal hyperalgesia and thermal
allodynia in the injured paw (Bennett and Xie, 1988). Within
three days of surgery, 89% of Aβ, 87% of Aδ, and 32% of C
fibers are lost, with progression to loss of 94% of myelinated
fibers and 73% of unmyelinated fibers within 14 days.
Electrophysiological studies have shown that primary
afferents, including large-diameter myelinated fibers, spontaneously discharge at ectopic foci proximal to the injury,
and these abnormal discharges may contribute to spontaneous and evoked manifestations of neuropathic pain
(Munger et al, 1992).
As shown in Table 5, mixed CB1/CB2 receptor agonists,
CB1-selective receptor agonists, and CB2 receptor-selective
agonists suppress increased nociceptive behavior in the CCI,
spinal nerve ligation (SNL) and partial sciatic nerve ligation
(pSNL) models. In the pSNL rat model, the potency of
WIN55,212-2 (0.1 mg/kg) in decreasing allodynia and
hyperalgesia was significantly greater when administered
daily prior to the surgery for 7 days, and for the following
2 weeks, than when administered only 2 weeks post-pSNL
(Guindon et al, 2007). These findings suggest that activation
of cannabinoid receptors can prevent the development of
pain induced by nerve injury. In both SNL and pSNL models,
the FAAH inhibitor URB597 evoked anti-allodynic (de
Novellis et al, 2011), as well as anti-hyperalgesic effects
(Desroches et al, 2008, 2014b). In addition, the fatty acid
amide PEA, a substrate of FAAH and an endogenous PPARα ligand, produces antinociceptive effects in a rat pSNL
model and in a mouse CCI model (Di Cesare Mannelli et al,
2013; Costa et al, 2008). Interestingly, daily administration of
PEA in a mouse model of CCI for a week produces a longlasting reduction of nociceptive behavior in nerve-injured
animals after cessation of PEA treatment (Costa et al, 2008).
It is noteworthy that FAAH inhibitors produce antinociceptive effects in the CCI model, without the development of
tolerance upon repeated administration (Schlosburg et al,
2010). In contrast, repeated administration of a high
dose of the MAGL inhibitor JZL184 leads to tolerance,
largely due to CB1 receptor downregulation and desensitization (Schlosburg et al, 2010). However, the antinociceptive
effects of a low-dose JZL184 are retained following repeated
administration in a mouse model of CCI (Kinsey et al, 2013),
suggesting that partial inhibition of MAGL is a viable
therapeutic strategy to minimize the likelihood of tolerance.
It is important to note that brain levels of 2-AG are
approximately three orders of magnitude higher than AEA
brain levels (Ahn et al, 2009). Thus, the disparity in tolerance
development in mice treated repeatedly with a MAGL
inhibitor vs a FAAH inhibitor may be related to differences
in mass action of these endocannabinoids. Other possible
factors contributing to the differential tolerance include
differences in the efficacy of 2-AG and AEA at cannabinoid
receptors and differences in CB1 receptor-mediated circuits
that these endocannabinoids activate.
The observation that selective inhibition of DAGL-β, the
biosynthetic enzyme expressed predominantly on

macrophages and microglia, reduces pro-inflammatory
mediators (Hsu et al, 2012), and reverses nociceptive
behavior in a mouse model of CCI (Wilkerson et al,
2016a) appears to be at odds with the antinociceptive
effects of MAGL inhibitors in this same model. These
apparent paradoxical findings were also true in models
of inflammatory pain, and can be reconciled when the
dual roles of 2-AG are considered. Specifically, as 2-AG is the
most highly expressed endocannabinoid in the CNS,
it not only plays a major role in cannabinoid receptor
activation, but also represents a rate-limiting precursor
of arachidonic acid in the CNS and immune cells.
Thus, inhibition of 2-AG hydrolysis or biosynthesis on
macrophages and microglia results in a reduction of
arachidonic acid and proinflammatory metabolites, which
can reduce nociceptive behavior through cannabinoid
receptor-independent mechanisms.

Streptozotocin-Induced Diabetes
Insulin-dependent diabetes is thought to cause one of the
most prevalent forms of peripheral neuropathy in the
developed world (Horowitz, 1993). Diabetic-induced neuropathic pain is difficult to treat and is generally unresponsive
to current analgesic therapies. Genetically-based diabetic
laboratory animal models include insulin deficient BB rats
and NOD mice, and insulin resistant ob/ob and db/db
mice. However, the most commonly used model of diabetic
neuropathy consists of a single systemic injection of
streptozotocin (STZ), which produces progressive and
permanent degeneration of the beta cells of the pancreatic
islets of Langerhans. This damage to beta cells leads to
hyperglycemia, polyuria, polydipsia and weight loss
(Katsilambros et al, 1970). STZ-induced diabetes produces
consistent, long-lasting thermal and mechanical hyperalgesia, in addition to cold and mechanical allodynia (Courteix
et al, 1993), associated with hyperexcitability of nociceptive
C fibers in response to mechanical stimuli. Importantly, STZ
injection elicits a time-dependent increase in the intensity of
hyperalgesia, over a 4-week observation period. This time
course might mimic the slow progression of painful
neuropathy in individuals with diabetes from the painful
stage to the degenerative and painless stage (Courteix et al,
1993). However, the mechanisms that produce neuropathic
pain in this model are still not well understood.
Several studies have demonstrated that THC (Williams
et al, 2008) and WIN55,212-2 (Bujalska, 2008; Doğrul et al,
2004; Ikeda et al, 2013; Jahanabadi et al, 2016; MohammadiFarani et al, 2010; Ulugol et al, 2004; Vera et al, 2012;
Vincenzi et al, 2013) produce antinociception in rodent STZinduced peripheral neuropathy. In particular, either single or
repeated administration of WIN55,212-2 or AM1241, dosedependently attenuated STZ-induced hyperalgesia (Bujalska,
2008). Furthermore, repeated administration for 1 month of
medium or high doses of intranasal WIN55,212-2 improved
thermal hyperalgesia and mechanical allodynia in STZtreated mice (Toth et al, 2010). In addition, FAAH (Hasanein
...................................................................................................................................................
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et al, 2009; Sasso et al, 2015) and MAGL (Niphakis et al,
2013) inhibitors reduce nociceptive behavior in STZ-injected
rats. Additionally, acute and repeated PEA administration
evoked anti-allodynic effects in diabetic mice without the
development of tolerance that required the activation of CB1,
CB2, TRPV1, PPAR-α and PPAR-γ receptors (Donvito et al,
2015) (Table 5).

By contrast, chronic administration of high-dose of
CP55,940 reverses paclitaxel-induced allodynia in CB1
( − / − ) mice. However, wild-type paclitaxel-injected mice
given 16 days of repeated administration of low-dose of
CP55,940 showed tolerance to the anti-allodynic effects. In
contrast, selective CB2 receptor agonists produce sustained
antinociceptive effects in this model without evidence of
tolerance (Deng et al, 2015a). Specifically, repeated systemic
administration of the CB2 receptor selective agonist AM1710
suppressed paclitaxel-induced allodynia without tolerance,
supporting the potential of prolonged use of CB2 receptor
agonists (Deng et al, 2015b). Additionally, selective inhibition of DAGL-β dose- and time-dependently reverses
mechanical allodynia in paclitaxel-injected mice (Wilkerson
et al, 2016a). Likewise, PEA elicited anti-allodynic effects in
paclitaxel-treated mice in a PPAR-α-dependent manner.
Repeated administration of PEA for 7 days did not produce
tolerance to its anti-allodynic effects (Donvito et al, 2016)
(Table 5).
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Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy (CIPN) is a
dose-limiting neurotoxic effect of chemotherapeutic agents
used to treat cancer. It is a common cause for early cessation
of cancer treatment and affects up to 70% of patients
receiving chemotherapy (Seretny et al, 2014). Patients with
CIPN experience symptoms of neuropathic pain such as
paraesthesia, dysesthesia, allodynia, and hyperalgesia, in
addition to numbness (Boyette-Davis et al, 2013). A wide
variety of chemotherapeutic agents, including taxanes,
platinum compounds, and vinca alkaloids, elicit similar
neurotoxic effects in rodents and patients. These chemotherapeutic agents indirectly induce neuropathy through different mechanisms of action, which result in damage to the
dorsal root ganglion satellite cells and Schwann cells that
support peripheral nerves. The net effect includes structural
damage, loss of peripheral nerve function, and hypersensitivity of remaining nerves. Furthermore, chemotherapeutic
agents induce mitochondrial dysfunction and mitochondriamediated oxidative stress, which lead to abnormal nerve
functionality and primary afferent neuron terminal or
intraepidermal nerve fiber degeneration (Han and Smith,
2013).

Paclitaxel-induced allodynia. Paclitaxel is an extremely
efficacious antineoplastic agent for the treatment of solid
tumors, but its significant side effects, such as neuropathy,
not only decrease quality of life but also can require changes
in treatment (Authier et al, 2009). Studies examining
different paclitaxel dosing regimens in rodents have led to
the development of standard protocols used in preclinical
studies. A single injection of paclitaxel (32 mg/kg, intraperitoneal) in rats produces mechanical and thermal
hyperalgesia, but does not elicit mechanical allodynia
(Authier et al, 2000). On the other hand, lower doses of
paclitaxel (eg, 0.5, 1, or 2 mg/kg, intraperitoneal) administered on alternate days for four injections elicit thermal and
mechanical hyperalgesia as well as allodynia to light touch
and cold stimuli (Polomano and Bennett, 2001). In rats,
behavioral signs of neuropathic pain are accompanied by
increased evoked activity and decreased conduction velocity
of a subpopulation of C fibers (Dina et al, 2001).
It has been reported that mixed CB1/CB2 receptor agonists
and CB2 receptor-selective agonists are effective against
paclitaxel-induced peripheral neuropathy (Deng et al, 2015a,
2015b; Pascual et al, 2005; Rahn et al, 2008). Notably, chronic
low-dose CP55,940 suppressed paclitaxel-induced allodynia
in wild-type and CB2 ( − / − ) mice, but not CB1 ( − / − ) mice.
...................................................................................................................................................
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Cisplatin-induced allodynia. Cisplatin is extensively used
alone or in combination with other neurotoxic agents in the
treatment of a variety of cancers, including testicular,
ovarian, bladder, and lung. Repeated injections of cisplatin
in rodents led to increased mechanical and thermal
sensitivity (Joseph and Levine, 2009) as well as produced
motor disorders (Verdú et al, 1999). Numerous neurophysiologic studies have shown that cisplatin decreases sensory
nerve conduction velocities and reduces the amplitude of
nerve action potentials (De Koning et al, 1987). Morphologic
observations indicate that the nucleolus of primary sensory
neurons is severely compromised in experimentally-induced
cisplatin neuropathy (Cavaletti et al, 1992). Moreover,
cisplatin damages myelinated nerve fibers (Boehmerle et al,
2014). Cisplatin may be expected to accumulate in dorsal
root ganglia, leading to nuclear damage and an alteration in
the peptide content, and can also exert its neurotoxic effects
through Schwann cells (Yamamoto et al, 1997).
Cisplatin administration leads to profound alterations in
the endogenous cannabinoid system. Specifically, cisplatin
injections alter endocannabinoid tone, upregulating FAAH
expression in the dorsal root ganglia (Guindon et al, 2013)
(see Table 5). Drugs targeting specific components of the
endocannabinoid system produce antinociceptive effects in
cisplatin-induced allodynia. For example, AEA, THC, and
WIN55,212-2 elicit antinociceptive effects in rodent models
of cisplatin-induced peripheral neuropathy through a
mechanism of action that requires activation of CB1
(Harris et al, 2016; Khasabova et al, 2012) and CB2 (Vera
et al, 2013) receptors. In addition, intraplantar injection of
AEA or URB597 transiently attenuated hyperalgesia through
activation of peripheral CB1 receptors. The development of
cisplatin-induced hyperalgesia was delayed, and its magnitude was reduced, when daily injections of cisplatin were
accompanied with URB597. This effect was mediated by the
CB1 receptor (Khasabova et al, 2012). Conversely, AM1710
suppressed the maintenance of mechanical and cold
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allodynia in the cisplatin model through a CB2 receptor
mechanism of action, with no evidence of CB1 receptor
involvement (Deng et al, 2012). Finally, FAAH and MAGL
inhibitors reduced cisplatin-induced mechanical and cold
allodynia, which are CB1 and CB2 receptors-mediated
(Guindon et al, 2013; Khasabova et al, 2014).

Vincristine-induced allodynia. Vincristine is prescribed to
treat acute leukemia, neuroblastoma, Hodgkin’s disease and
other lymphomas. Vincristine arrests mitosis by binding to
tubulin and blocking microtubule polymerization. In rats, 10
daily injections of vincristine (0.02, 0.1, or 0.2 mg/kg,
intravenous) with a 2-day drug-free interval after the fifth
day, induced hyperalgesia (Aley et al, 1996), and allodynia
(Authier et al, 1999). Electrophysiological evaluations
showed that vincristine caused decreased conduction velocity
in myelinated and unmyelinated fibers and enhanced
responsiveness of C fibers to thermal and mechanical
stimuli, but did not change spontaneous activity, activation
thresholds, or the number of myelinated and unmyelinated
fibers (Tanner et al, 1998). Additionally, vincristine treatment resulted in higher firing frequency and variability in
C-fibers, suggesting that alterations of activity-dependent
post-synaptic effects in sensory pathways might produce a
state of enhanced pain (Tanner et al, 1998).
Mixed CB1/CB2 receptor agonists and CB2 selective
receptor agonists reduce nociceptive behavior in
vincristine-treated rats (Rahn et al, 2007) (see Table 5).
In particular, systemic administration of WIN55,212-2
suppresses vincristine-evoked mechanical allodynia through
a CB1 and CB2-dependent mechanism. In addition, AM1241
reverses vincristine-induced mechanical hypersensitivity
through a CB2 receptor mechanism of action. Spinal
administration of WIN55,212-2 suppressed vincristineevoked mechanical hypersensitivity at doses that were
inactive following intraplantar administration. These effects
were blocked by intrathecal co-administration of rimonabant
and SR144528, implicating both CB1 and CB2 receptors
(Rahn et al, 2007).

Models of Migraine Headache
Migraine is a neurological disorder characterized by
recurrent debilitating attacks of headache and is the
second-most common neurological disorder that accounts
for more than half of the number of years lived with
disability attributable to neurological diseases (Vos et al,
2012). Chronic migraine occurs when headaches and associated symptoms occur on more than 15 days per month,
for at least 3 months, and meet diagnostic criteria for
migraine with or without aura on at least 8 days per month
(Headache Classification Committee of the International
Headache Society (IHS), 2013). Patients with chronic
migraine experience pain and other symptoms, including
nausea, vomiting, osmophobia, photophobia, and phonophobia in addition to cutaneous allodynia in cranial receptive
fields of the ophthalmic division of the trigeminal nerve

(Cooke et al, 2007; Diener et al, 2012). Current animal
models of chronic migraine include recurrent activation of
the trigeminal nociceptive system by repeated direct or
indirect stimulation of the trigeminovascular and meningeal
afferents through inflammatory mediators (Melo-Carrillo
and Lopez-Avila, 2013) or injection of chemicals (that is,
glycerol trinitrate) (Pradhan et al, 2014). Other models are
based on genetic modifications (Estevez, 2006), and chronic
alteration of the endogenous pain modulating system
through serotonin depletion (Cui et al, 2013).
FAAH inhibitors (ie, PF-3845 and URB597) reverse
allodynia in a mouse model of nitroglycerin-induced
migraine through a CB1 receptor-dependent mechanism
(Nozaki et al, 2015). Others have found that the peripherally
restricted FAAH inhibitor URB937 administration evoked
anti-hyperalgesic effect in rats (Greco et al, 2015). Additionally, CB2 agonism evokes an analgesic effect in a rat model of
migraine (Greco et al, 2014) (see Table 5). Another study
shows that nitroglycerin-induced hyperalgesia in rats is
associated with increased activity of both FAAH and MAGL,
and increased density of cannabinoid receptors binding sites
in the mesencephalon. In the hypothalamus, the activity
of FAAH and the density of cannabinoid binding sites is
also enhanced, while in the medulla only the activity of
FAAH increases (Greco et al, 2010). AEA also abolishes
nitroglycerin-induced hyperalgesia in the phase II of
formalin test (Greco et al, 2011). These studies suggest that
a dysfunction of the endocannabinoid system may contribute
to the development of migraine attacks and modulation of
this system can be useful for the treatment of pain associated
to migraine.

OPIOID-SPARING EFFECTS: PRECLINICAL
STUDIES
Although opioids are widely accepted for the treatment of
chronic pathological pain (Ballantyne and Mao, 2003), recent
restructuring of prescription recommendations, particularly
within the United States, strongly regulate their dosing
(Dowell et al, 2016). These recommendations have arisen
due to the epidemic of opioid misuse and abuse, as the use of
opioids carries a high abuse potential (Thomas et al, 2015)
with prescription opioid misuse preceding ~80% of new
heroin users in the United States (Hedegaard et al, 2015).
The combination of opioids with other classes of analgesics is
a promising strategy to minimize abuse potential, and other
opioid-related side effects (eg, sedation, constipation, physical dependence, tolerance, and respiratory depression)
(Benyamin et al, 2008). Indeed, archaeological evidence
describes the use of cannabis and opium salve for athletic
injury (Bartels et al, 2006). Moreover, preclinical evidence
demonstrates co-expression of CB1 receptors and MORs in
the periaqueductal gray and the co-administration of
HU-210 and morphine into this brain region produces
enhanced antinociceptive effects (Wilson-Poe et al, 2012,
2013). CB1 receptors and MORs are also co-expressed within
...................................................................................................................................................
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the dorsal horn of the spinal cord (Desroches et al, 2014a; da
Fonseca Pacheco et al, 2008). Of importance, these receptors
share similar signal transduction pathways (Rios et al, 2006).
Accordingly, emerging preclinical evidence shows that
activation of cannabinoid receptors, via direct actions by
CB1/CB2 agonists, or via MAGL and/or FAAH inhibition,
represents a promising opioid-sparing therapeutic option for
acute, inflammatory, and neuropathic pain. The reduction in
opioid dose is described here as ‘opioid-sparing effects’.

that cannabinoids can augment the antinociceptive effects of
opioids, which from a translational perspective could be of
great benefit to reduce to opioid dosing in pain patients,
though the increased rate of tolerance in nonhuman
primates presents some concern.
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Acute Pain Models
Cannabinoid receptor agonists augment the antinociceptive
effects of opioids in preclinical models of acute pain,
suggesting that cannabinoid agonists are opioid-sparing
(Mecs et al, 2010; Tham et al, 2005; Tuboly et al, 2009).
For example, the combination of CP55,940 and morphine
synergistically attenuates thermal nociception in mice (Tham
et al, 2005). Further, administration of a low dose of THC in
combination with morphine prevents tolerance to morphine
in the tail flick assay for acute pain (Cichewicz and Welch,
2003). Further studies indicate that the combination of THC
and morphine produces synergistic antinociception in the
tail flick assay (Cichewicz and McCarthy, 2003). In the
hotplate assay for antinociception, pretreatment with
CP55,940 (0.1 mg/kg), a dose that is ineffective by itself,
produces a leftward shift in the dose-response of morphine
(Miller et al, 2012). Additionally, CP55,940 produces a
leftward shift of the morphine dose–response curve in the
acetic acid abdominal stretching model of visceral pain in
mice (Miller et al, 2012). Similarly, combination of URB597
and morphine produces additive antinociceptive effects in
the acetic acid abdominal stretching assay and depressed
wheel running in mice (Miller et al, 2012).
In addition to rodent models, combination of opioids and
cannabinoids produces enhanced antinociceptive effects in
nonhuman primates. Specifically, combined administration
of morphine and THC produces augmented antinociceptive
effects in the rhesus monkey warm water withdrawal test
(Gerak and France, 2016; Li et al, 2008). Subthreshold doses
of either CP55,940 or WIN55212-2 produce leftward shifts of
the morphine dose-response curve in this assay, but elicit
rightward and downward shifts of the morphine dose
response curves in the drug discrimination and selfadministration assays (Maguire et al, 2013), suggesting
decreased abuse liability. Likewise, subthreshold doses of
THC or CP55,940 produce leftward shifts in the antinociceptive dose–response relationships of fentanyl, etorphine,
and buprenorphine, with increased shifts for the highefficacy MOR agonists compared with the low-efficacy MOR
agonists (Maguire and France, 2014, 2016). In contrast to
work conducted on rodents (Smith et al, 2007), the
combination of opioids and cannabinoids results in increased antinociceptive tolerance and cross-tolerance to
opioids in nonhuman primates (Gerak and France, 2016),
which underscores the importance of testing in higher
animals. In summary, these studies provide strong evidence
...................................................................................................................................................
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Inflammatory Pain Models
Cannabinoid receptor agonists significantly decrease the
dose of opioids needed to produce antinociception in several
models of inflammatory pain, and potentially reduces
opioid-induced side-effect profiles such as constipation and
depressed respiration. Co-administration of THC and
morphine produces synergistic antinociceptive effects in
the rat CFA arthritis model (Cox et al, 2007). Several pieces
of evidence suggest cross-talk between cannabinoids and the
endogenous opioid system. For example, naloxone blocks the
antinociceptive effects of THC in both arthritic and nonarthritic rats (Cox and Welch, 2004; Smith et al, 1998).
Furthermore, THC attenuates spinal dynorphin levels in
arthritic rats, indicating interactions between the opioid and
endocannabinoid systems (Cox and Welch, 2004). Few
studies are investigating the anatomical site of regulation of
opioid-sparing effects under pathological pain conditions.
Intrathecal co-administration of the endogenous opioid
peptide endomorphin-1 (EM-1) and the endocannabinoid
AEA reverses carrageenan-induced thermal hyperalgesia,
suggesting a spinal site of action (Tuboly et al, 2009).
Combined peripheral administration of the endogenous
opioid peptide EM-1 and the endocannabinoid 2-AG
attenuates mechanical allodynia produced by intra-articular
injection of carrageenan, but did not affect edema (Mecs
et al, 2010). Interestingly, a local, intraplantar coadministration of the CB1 receptor agonist arachidonylcyclopropylamide (ACPA) with the mu-opioid receptor
agonist DAMGO produces antagonistic effects on each
respective compound’s antinociceptive properties in the rat
CFA model of inflammatory pain (Auh et al, 2016). Finally,
co-administration of the CB2 receptor agonist JWH015 and
morphine produces synergistic effects in the rat formalin
model of inflammatory pain (Grenald et al, 2016).

Neuropathic Pain Models
Recent evidence supports that cannabinoids are also opioidsparing in models of neuropathic pain. Combination of
morphine and the cannabinoid receptor agonist WIN55,212
produces synergistic anti-mechanical and cold allodynia in
the mouse CCI model of neuropathic pain but acts in an
additive manner in the impairment of motor coordination as
assessed with the rotarod assay (Kazantzis et al, 2016). In
addition, the co-administration of the CB2 receptor agonist
JWH015 and morphine produces synergistic effects in the rat
SNI model of neuropathic pain (Grenald et al, 2016).
The MAGL inhibitor MJN110 interacts in a synergistic
manner with morphine to reverse allodynia and thermal
hyperalgesia in the mouse CCI model, without opioid-
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induced constipation or cannabinoid subjective effects.
Importantly, these antinociceptive effects do not undergo
tolerance after six days of repeated administration. CB1
receptors, CB2 receptors, and MORs are necessary to
produce the observed antinociceptive effects (Wilkerson
et al, 2016b). Additionally, SA-57, a dual FAAH-MAGL
inhibitor that inhibits FAAH at considerably lower doses
than it inhibits MAGL, interacts in an additive manner with
morphine to reverse allodynia in the mouse CCI model
(Wilkerson et al, 2017), while only producing antinociception in the tetrad assay for cannabimimetic effects. Notably,
SA-57 also diminishes drug seeking behavior in mice trained
to nose poke for heroin (Wilkerson et al, 2017).

Potential Underlying Mechanisms
There are several potential underlying neuronal and
immunological mechanisms for the opioid-sparing actions
of cannabinoids. One intriguing explanation accounting for
the effects produced by CBD is that it may act as a positive
allosteric modulator of opioid receptors (Kathmann et al,
2006). In addition to the above described influence of the
CB1 receptor on neuronal dynorphin release, CB1 receptors
and MORs form heterodimers, which account for enhanced
neuronal antinociceptive interactions of cannabinoids and
opioids (Rios et al, 2006). In the periphery, CB2 receptor
agonists lead to endorphin release from keratinocytes
(Ibrahim et al, 2005). Moreover, an overwhelming amount
of evidence demonstrates that within the CNS, opioid
administration leads to the activation of microglia via a
toll-like receptor (TLR)-4-dependent mechanism, and produces paradoxical aggravation of proinflammatory immune
responses (Hutchinson et al, 2007; Watkins et al, 2009).
Although speculative, CB2 receptor agonists may reduce
these proinflammatory actions of opioids, thus further
enhancing antinociceptive effects. Specifically, it has been
found that, within the CNS, CB2 receptor agonists increase
the anti-inflammatory cytokine IL-10, decrease IL-1β
(Wilkerson et al, 2012a, 2012b), decrease signaling within
the AKT-ERK1/2 pathway (Merighi et al, 2012) and reduce
mRNA of monocyte chemoattractant protein 1 (MCP-1)/
CCL2 (Deng et al, 2015a).
In summary, opioid-cannabinoid combinations lead to
enhanced antinociception in laboratory animal pain models
but do not increase untoward side effects of opioids, such as
respiratory depression, abuse liability (Gerak and France,
2016) or constipation (Wilkerson et al, 2016b). Overall, these
results indicate that the actions of either direct CB1/CB2
receptor agonists or the inhibition of endocannabinoid
degradative enzymes are a novel therapeutic avenue to
decrease the doses of opioids needed for clinical pain control,
and warrants further clinical investigation. Indeed, a recent
meta-analysis study reported strong evidence that cannabinoids produce opioid-sparing effects in preclinical studies,
but only a single study of nine clinical studies provided
evidence of opioid-sparing effects in humans (Nielsen et al,
2017).

CANNABINOIDS AND CLINICAL
MANAGEMENT OF PAIN
A comprehensive meta-analysis shows that medicinal
cannabis and cannabinoids effectively alleviate different
types of pain, such as neuropathic, fibromyalgia, multiple
sclerosis, cancer, diabetic neuropathy, refractory pain due to
multiple sclerosis or other neurological conditions, rheumatoid arthritis, noncancer pain, central pain, musculoskeletal
problems, and chemotherapy-induced pain (Whiting et al,
2015). Here we highlight relatively recent studies examining
the effectiveness of cannabinoids in the clinical management
of pain as a number of comprehensive other reviews have
recently been published (Lynch and Campbell, 2011; Lynch
and Ware, 2015; Stevens and Higgins, 2017).
In studies evaluating smoked cannabis using cigarettes
with varying THC contents, significant improvements in
pain were observed compared to placebo. In neuropathic
pain, cannabis containing both a lower dose (1.29 % THC)
and higher dose (3.53 % THC) delivered by vaporizer
demonstrated a significant analgesic response (Wilsey et al,
2013). In a study of multiple sclerosis spasticity and pain,
smoked cannabis containing 4 % THC demonstrated a
significant anti-spasticity and analgesic effect compared with
placebo (Corey-Bloom et al, 2012). A randomized, doubleblinded, placebo controlled study conducted in patients with
painful diabetic peripheral neuropathy using different
formulation of inhaled cannabis showed a significant dosedependent effect on spontaneous pain score and allodynia
(Wallace et al, 2015).
The oromucosal spray Sativex that contains an equal
mixture of THC and CBD (approved in Canada and
European countries) demonstrated a significant analgesic
effect in neuropathic pain (Serpell et al, 2014). In a study
involving neuropathic pain in multiple sclerosis patients,
Sativex reduced pain compared to placebo at 10 weeks.
However, after 14 weeks, there was no difference between
oral mucosal cannabis spray and placebo groups (Langford
et al, 2013). In a pilot study of chemotherapy-induced
neuropathic pain, no statistically significant difference in
pain scores was found in the oromucosal-treated group, as
compared to the placebo group, although five of the 16
participants reported a 2-point grade reduction of pain score
(Lynch et al, 2014). Recently, patients with progressive
multiple sclerosis treated with an oral formulation of THC
reported a significant reduction of pain (van Amerongen
et al, 2017). Notably, this formulation was well tolerated and
had a stable pharmacokinetic profile.
Nabilone, a synthetic THC analogue approved by the FDA
for treatment of chemotherapy-induced nausea and vomiting
(Pertwee, 2012), has also been evaluated for the treatment of
pain. In a study of medication overuse headache, nabilone
was superior to ibuprofen in reducing daily analgesic intake
and pain intensity (Pini et al, 2012). Furthermore, nabilone
was significantly more effective than placebo in reducing
pain in patients with painful diabetic neuropathy (Toth et al,
2012). In a study using amitriptyline as an active control
...................................................................................................................................................
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examining sleep with pain as a secondary measure in
fibromyalgia, there was no significant pain reduction (Ware
et al, 2010). However, nabilone in combination with
gabapentin improved pain reporting significantly more than
gabapentin alone in multiple sclerosis patients (Turcotte
et al, 2015).
A growing body of the preclinical data suggesting that
cannabinoids in combination with opioids may lead to
increased analgesic effects, while producing opioid-sparing
effects in studies evaluating the clinical management of pain.
A double-blind study conducted in an experimental pain
model involving thermal stimuli applied to normal subjects
investigated whether THC potentiates the analgesic effects of
morphine (Roberts et al, 2006). In this study, the doses of
morphine or THC used alone did not elicit a significant
analgesic effect, but combination of the drugs showed an
enhanced analgesic effect with respect to the affective
component of pain. Indeed, the management of the affective
component of pain may be especially relevant to the clinical
problem of chronic pain. A phase I, and phase II study
examining the efficacy of THC as an adjunct to opioid
therapy for the treatment of chronic pain showed that THC
enhanced pain relief in patients under opioid therapeutic
regimen (Narang et al, 2008).
Although several studies show that ‘medical cannabis’ can
improve various types of pain, cannabimimetic side effects,
which include drowsiness or fatigue, dizziness, dry mouth,
nausea, and cognitive effects, have also been reported
(Whiting et al, 2015). Thus, additional research is needed
to improve study methodologies, including the use of
standard formulations and/or dosages, the increase in the
number of subjects involved, and the general determination
of the safe and effective use of cannabis for the treatment of
human pain.
At the present time, there is only a single published clinical
report examining whether inhibition of an endocannabinoidregulating enzyme relieves pain. In this study, the FAAH
inhibitor PF-04457845 failed to relieve pain related to
osteoarthritis of the knee, as compared with placebo
(Huggins et al, 2012). As FAAH inhibitors produce reliable
antinociceptive effects in preclinical osteoarthritis models
(Table 4), the lack of translation may be related to species
differences or masked by the expectancy effect caused by the
placebo in the clinical trial, though the comparison drug
naproxen significantly improved pain compared with
placebo. Also, it was not explored whether PF-04457845 in
combination with naproxen would have resulted in enhanced antinociceptive effects compared with naproxen
alone. In light of the death and adverse events in other
subjects given repeated high doses of the FAAH inhibitor
BIA-102474-101 in a clinical trial (Kerbrat et al, 2016), it is
crucial to note that this drug has multitude of off-targets,
including inhibition of essential blood-clotting factors
thrombin and Factor VII (van Esbroeck et al, 2017;
Molinski et al, 2017), which may contributed to its toxicity.
It is also important to recognize that the highly selective
FAAH inhibitor PF-04457845 was well tolerated in the

patients, with no evidence of serious adverse events (Huggins
et al, 2012).
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CONCLUSIONS AND FUTURE DIRECTIONS
An overwhelming body of convincing preclinical evidence
indicates that cannabinoids produce antinociceptive effects
in inflammatory and neuropathic rodent pain models.
Cannabinoid receptor agonists, endocannabinoid-regulating
enzyme inhibitors, and other pharmacological strategies to
manipulate the endogenous cannabinoids system decrease
the hyperalgesia and allodynia induced in diverse inflammatory and neuropathic pain states. In particular, the
endocannabinoid degradative enzymes FAAH and MAGL
are attractive targets for drug development.
The results of clinical studies consistently demonstrate
efficacy of cannabis and cannabinoid receptor agonists in
reducing diverse neuropathic pain states in humans.
However, adverse effects associated with use of ‘medical
cannabis’ as well as challenges in ensuring standardized plant
constituents and concerns related to inhaling pyrolysis
products of smoked cannabis are large hurdles in developing
the entire plant as medicine. Thus, further research is needed
to investigate whether other constituents of cannabis besides
THC have therapeutic efficacy (for example, CBD) as well as
explore safer delivery routes than smoking. Additionally,
medicinal chemistry holds great promise to develop
cannabimimetic agents that lack cannabimimetic side effects
by synthesizing CB1 receptor PAMs, selective CB2 receptor
agonists, and selective inhibitors of endocannabinoid regulating enzymes and endocannabinoid transport. Undoubtedly, drug formulation will direct the development of new
cannabinoid-based medications. In addition, the combination of cannabinoids with conventional analgesics (for
example, opioids, NSAIDs, gabapentin) is a promising
avenue by which to increase efficacy and reduce side effects.
In sum, the endogenous cannabinoid system contains
multiple promising therapeutic targets and provides a strong
impetus to develop cannabinoid-based medications to treat
inflammatory and neuropathic pain.
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